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REAMBLE
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures and
herapies as they are introduced and tested in the detection,
anagement, or prevention of disease states. Rigorous and
xpert analysis of the available data documenting absolute and
elative benefits and risks of those procedures and therapies can
roduce helpful guidelines that improve the effectiveness of
are, optimize patient outcomes, and favorably affect the overall
ost of care by focusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
nd the American Heart Association (AHA) have jointly
ngaged in the production of such guidelines in the area of
ardiovascular disease since 1980. The ACC/AHA Task Force
n Practice Guidelines, whose charge is to develop, update, or
evise practice guidelines for important cardiovascular diseases
nd procedures, directs this effort. The Task Force is pleased to
ave this guideline developed in conjunction with the Euro-
ean Society of Cardiology (ESC). Writing committees are
harged with the task of performing an assessment of the
vidence and acting as an independent group of authors to
evelop or update written recommendations for clinical practice.
Experts in the subject under consideration have been se-
ected from all 3 organizations to examine subject-specific data
nd write guidelines. The process includes additional represen- patives from other medical practitioner and specialty groups
hen appropriate. Writing committees are specifically charged
o perform a formal literature review, weigh the strength of
vidence for or against a particular treatment or procedure, and
nclude estimates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of patient
reference that might influence the choice of particular tests or
herapies are considered as well as frequency of follow-up and
ost effectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy and
linical outcomes will constitute the primary basis for preparing
ecommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and
he ESC Committee for Practice Guidelines make every effort
o avoid any actual, potential, or perceived conflict of interest
hat might arise as a result of an industry relationship or
ersonal interest of the writing committee. Specifically, all
embers of the writing committee, as well as peer reviewers of
he document, were asked to provide disclosure statements of
ll such relationships that might be perceived as real or
otential conflicts of interest. Writing committee members are
lso strongly encouraged to declare a previous relationship with
ndustry that might be perceived as relevant to guideline
evelopment. If a writing committee member develops a new
elationship with industry during his or her tenure, he or she is
equired to notify guideline staff in writing. The continued
articipation of the writing committee member will be re-
iewed. These statements are reviewed by the parent task force,
eported orally to all members of the writing committee at each
eeting, and updated and reviewed by the writing committee
s changes occur. Please refer to the methodology manuals for
urther description of the policies used in guideline develop-
ent, including relationships with industry, which are available
n the ACC, AHA, and ESC World Wide Web sites
http://www.acc.org/clinical/manual/manual_introltr.htm,
ttp://circ.ahajournals.org/manual/, and http://
ww.escardio.org/knowledge/guidelines/Rules/, respectively).
lease see Appendix 1 for author relationships with industry
nd Appendix 2 for peer reviewer relationships with industry
hat are pertinent to these guidelines.
These practice guidelines are intended to assist health care
roviders in clinical decision making by describing a range of
enerally acceptable approaches for the diagnosis and manage-
ent of specific diseases or conditions. These guidelines
ttempt to define practices that meet the needs of most patients
n most circumstances. These guideline recommendations
eflect a consensus of expert opinion after a thorough review of
he available, current scientific evidence and are intended to
mprove patient care. If these guidelines are used as the basis
or regulatory/payer decisions, the ultimate goal is quality of
are and serving the patient’s best interests. The ultimate
udgment regarding care of a particular patient must be made
y the healthcare provider and the patient in light of all of the
ircumstances presented by that patient. There are circum-
tances in which deviations from these guidelines are appro-
riate.
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HA Task Force on Practice Guidelines and the ESC
ommittee for Practice Guidelines and will be consid-
red current unless they are updated, revised, or sunsetted
nd withdrawn from distribution. The executive sum-
ary and recommendations are published in the Septem-
er 5, 2006 issue of the Journal of the American College of
ardiology, the September 5, 2006 issue of Circulation,
nd the September 17, 2006 issue of the European
eart Journal. The full-text guideline is e-published in
he September 5, 2006 issue of the Journal of the American
ollege of Cardiology, the September 5, 2006 issue of
irculation, and the September 2006 issue of Europace, as
ell as posted on the ACC (www.acc.org), AHA (www.
mericanheart.org), and ESC (www.escardio.org) World
ide Web sites. Copies of the full text and the executive
ummary are available from all 3 organizations.
Sidney C. Smith Jr., MD, FACC, FAHA, FESC,
Chair, ACC/AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC,
Chair, ESC Committee for Practice Guidelines
able 1. Clinical Practice Guidelines and Policy Statements That
atients with Ventricular Arrhythmias and the Prevention of SCD
Document
uidelines
SCD ESC
Syncope ESC
Exercise testing ACC
Cardiac pacemakers and antiarrhythmia devices ACC
Echocardiography ACC
Supraventricular arrhythmias ACC
SCD Update ESC
Congenital heart disease ESC
European guidelines on CVD prevention ESC
Infective endocarditis ESC
Pericardial disease ESC
Pulmonary arterial hypertension ESC
AED use in Europe ESC
ST-elevation myocardial infarction ACC
Chronic heart failure ACC
Chronic heart failure ESC
CPR and ECC AH
Resuscitation ERC
Valvular heart disease ACC
tatements
Invasive electrophysiology studies, catheter ablation, and
cardioversion
ACC
Hypertrophic cardiomyopathy ACC
Cardiovascular disease during pregnancy ESC
Physical activity and recreational sports AHA for young
patients with genetic CVD
36th Bethesda Conference: Eligibility recommendations for
competitive athletes with cardiovascular abnormalities
ACC
he guidelines from the ACC, AHA, and ESC are available at www.acc.org, www.
ACC  American College of Cardiology; AHA  American Heart Association;ardiovascular care; ERC  European Resuscitation Council; ESC  European Socie
ASPE Heart Rhythm Society (formerly North American Society for Pacing and Elect. INTRODUCTION
everal excellent guidelines already exist on treating patients
ho have ventricular arrhythmias (Table 1). The purpose of
his document is to update and combine the previously
ublished recommendations into one source approved by
he major cardiology organizations in the United States and
urope. We have consciously attempted to create a stream-
ined document, not a textbook that would be useful
pecifically to locate recommendations on the evaluation
nd treatment of patients who have or may be at risk for
entricular arrhythmias. Thus, sections on epidemiology,
echanisms and substrates, and clinical presentations are
rief, because there are no recommendations for those
ections. For the other sections, the wording has been kept
o a minimum, and clinical presentations have been con-
ned to those aspects relevant to forming recommendations.
The reader should note that the recommendations, text,
gures, and tables included in this executive summary
epresent a succinct summary of the more extensive evidence
ase, critical evaluation, supporting text, tables, figures, and
eferences that are included in the full-text guidelines.
rlap With ACC/AHA/ESC Guidelines for the Management of
nsor Citation
Eur Heart J 2001;22:1374–450
Eur Heart J 2004;25:2054–72
A Circulation 2002;106:1883–92
A/NASPE Circulation 2002;106:2145–61
A J Am Coll Cardiol 2003;42:954–70
A/ESC Eur Heart J 2003;24:1857–97
J Am Coll Cardiol 2003;42:1493–531
Eur Heart J 2003;24:13–5
Eur Heart J 2003;24:1035–84
Eur J Cardiovasc Prev Rehab 2003;10 Suppl 1:S1–78
Eur Heart J 2004;25:267–76
Eur Heart J 2004;25:587–610
Eur Heart J 2004;25:2243–78
Eur Heart J 2004;25:437–45
A J Am Coll Cardiol 2004;44:e1–211
A J Am Coll Cardiol 2005;46:e1–82
Eur Heart J 2005;26:1115–40
OR Circulation 2005;112:IV-1–203
Resuscitation 2005;67 Suppl:539–86
A J Am Coll Cardiol 2006;48:e1–148
A J Am Coll Cardiol 2000;36:1725–36
C Eur Heart J 2003;24:1965–91
J Am Coll Cardiol 2003;42:1687–713
Eur Heart J 2003;24:761–81
Circulation 2004;109:2807–16
J Am Coll Cardiol 2005;45:1318–75
anheart.org, and www.escardio.org, respectively.
 cardiovascular disease; CPR  cardiopulmonary resuscitation; ECC  emergencyOve
Spo
/AH
/AH
/AH
/AH
/ERC
/AH
/AH
A/ILC
/AH
/AH
/ES
americ
CVDty of Cardiology; ILCOR  International Liaison Committee on Resuscitation;
rophysiology); SCD  sudden cardiac death.
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uidelines.
The final recommendations for indications for a diagnos-
ic procedure, a particular therapy, or an intervention for
anagement of patients with ventricular arrhythmias and
revention of sudden cardiac death summarize both clinical
vidence and expert opinion. Classification of Recommen-
ations and Level of Evidence are expressed in the ACC/
HA/ESC format as follows:
lassification of Recommendations
● Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment
is beneficial, useful, and effective.
● Class II: Conditions for which there is conflicting
evidence and/or divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
● Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
● Class IIb: Usefulness/efficacy is less well estab-
lished by evidence/opinion.
● Class III: Conditions for which there is evidence
and/or general agreement that a procedure/treatment
is not useful/effective and in some cases may be
harmful.
evel of Evidence
Level of Evidence A: Data derived from multiple
randomized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single
randomized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of ex-
perts, case studies, or standard-of-care.
The schema for classification of recommendations and
evel of evidence is summarized in Table 2, which also
llustrates how the grading system provides an estimate of
he size of treatment effect and an estimate of the certainty
f the treatment effect.
Recommendations with respect to therapy have considered:
. The therapy to be offered (implantable cardioverter-
defibrillator [ICD], antiarrhythmic drugs, surgery, and
miscellaneous other treatments)
. The point at which therapy is offered (primary preven-
tion for those who are at risk but have not yet suffered
from a life-threatening ventricular arrhythmia or sud-
den cardiac “death” episode, or secondary for those
patients who have already experienced such arrhyth-
mias or events),
. The purpose of therapy (life preservation or symptom
reduction/improved quality of life)
. The etiology of the arrhythmia substrate (coronary
heart disease, cardiomyopathy, or other conditions)
. The functional status of the patient (New York Heart
Association [NYHA] class) i. The state of left ventricular (LV) function (left ventric-
ular ejection fraction [LVEF]), and
. The specific arrhythmia concerned (e.g., sustained
monomorphic ventricular tachycardia [VT], polymor-
phic VT, and ventricular fibrillation [VF])
Not all therapeutic combinations are clinically relevant
nd many have no evidence base and probably will not
ave in the future because of the lack of clinical relevance
r the relative rarity of the particular grouping. In many
nstances, the probable value of therapy may be reason-
bly inferred by the response of similar patients to specific
herapies.
. Prophylactic Implantable Cardioverter-Defibrillator
ecommendations Across Published Guidelines
he ACC/AHA/NASPE 2002 Guidelines Update for
mplantation of Cardiac Pacemakers and Antiarrhythmia
evices (1), the ACC/AHA 2004 Guidelines for the
anagement of Patients With ST-Elevation Myocardial
nfarction (2), the ESC 2001 and 2003 Guidelines on
revention of Sudden Cardiac Death (3,4), the ESC 2005
uidelines for the Diagnosis and Treatment of Chronic
eart Failure (5) and the ACC/AHA 2005 Guideline
pdate for the Diagnosis and Management of Chronic
eart Failure in the Adult (6) include a large number of
ecommendations on ICD therapy that merit attention.
Recommendations for prophylactic ICD implantation
ased on (EFs) have been inconsistent because clinical
nvestigators have chosen different EFs for enrollment in
rials of therapy, average values of the EF in such trials have
een substantially lower than the cutoff value for enroll-
ent, and subgroup analysis of clinical trial populations
ased on EF have not been consistent in their implications.
ubstantial differences among guidelines have resulted.
owever, no trial has randomized patients with an inter-
ediate range of EFs. For instance, there is no trial that has
pecifically studied patients with a LVEF between 31% and
5%, and yet recommendations have been set for such
atients on the basis of data derived from trials that studied
roups with EFs less than or equal to 30%, others that
nrolled patients with an EF less than or equal to 35%, and
nother that enrolled patients with an EF less than or equal
o 40%. Recognizing these inconsistencies, this Guideline
riting Committee has decided to deal with the issue by
onstructing recommendations to apply to patients with an
F less than or equal to a range of values. The highest
ppropriate class of recommendation was then based on all
rials that recruited patients with EFs within this range. In
his way, potential conflicts between guidelines were re-
uced and errors due to drawing false conclusions relating to
nstudied patient groups were minimized (see Table 3).
It is important to note that experts can review the same
ata and arrive at different interpretations. Attempting to
omogenize heterogeneous trials invariably leads to varyingnterpretations of the trial data. Furthermore, differences
Table 2. Applying Classification of Recommendations and Level of Evidence†
“SIZE of TREATMENT EFFECT” 
Class I 
  
Benefit >>> Risk 
 
 
Procedure/Treatment
SHOULD be 
performed/administered
Class IIa 
  
Benefit >> Risk 
Additional studies with focused 
objectives needed 
 
IT IS REASONABLE to perform 
procedure/administer treatment 
Class IIb 
  
Benefit ≥ Risk 
Additional studies with broad 
objectives needed; Additional 
registry data would be helpful
Procedure/Treatment
MAY BE CONSIDERED
Level A 
  
 
Multiple (3-5) population risk 
strata evaluated* 
 
General consistency of direction 
and magnitude of effect
• Recommendation that 
procedure or treatment is 
useful/effective
• Sufficient evidence from 
multiple randomized trials or 
meta-analyses
• Recommendation in favor of 
treatment or procedure being 
useful/effective
• Some conflicting evidence from 
multiple randomized trials or 
meta-analyses
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from multiple randomized trials 
or meta-analyses 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Sufficient evidence from 
multiple randomized trials or 
meta-analyses
Level B 
 
Limited (2-3) population risk 
strata evaluated* 
 
• Recommendation that 
procedure or treatment is 
useful/effective
• Limited evidence from single 
randomized trial or non-
randomized studies 
• Recommendation in favor of 
treatment or procedure being 
useful/ effective 
• Some conflicting evidence from 
single randomized trial or non-
randomized studies 
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from single randomized trial or 
non-randomized studies 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Limited evidence from single 
randomized trial or non-
randomized studies 
Level C 
  
Very limited (1-2) population risk 
strata evaluated* 
 
 
• Recommendation that
procedure or treatment is 
useful/effective
• Only expert opinion, case 
studies, or standard-of-care 
• Recommendation in favor of 
treatment or procedure being 
useful/ effective 
• Only diverging expert opinion, 
case studies, or standard-of-
care
• Recommendation’s 
usefulness/efficacy less well 
established
• Only diverging expert opinion, 
case studies, or standard-of-care
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Only expert opinion, case 
studies, or standard-of-care 
“
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Class III 
  
Risk ≥ Benefit 
No additional studies needed 
 
Procedure/Treatment should 
NOT be performed/administered 
SINCE IT IS NOT HELPFUL 
AND MAY BE HARMFUL 
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. †A recommendation with
a Level of Evidence of B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available,
there may be a very clear consensus that a particular therapy is useful or effective.
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ecommendations are implemented. Guidelines are com-
osed of recommendations on the basis of the best available
edical science; however, implementation of these recom-
endations will be impacted by the financial, cultural, and
ocietal differences among individual countries.
. Classification of Ventricular
rrhythmias and Sudden Cardiac Death
his classification table is provided for direction and intro-
uction to the guidelines (Table 4).
I. INCIDENCE OF SUDDEN CARDIAC DEATH
he geographic incidence of sudden cardiac death (SCD)
aries as a function of coronary heart disease (CHD)
revalence in different regions (3). Estimates for the United
tates (9–13) range from less than 200 000 to more than
50 000 SCDs annually, with the most widely used esti-
ates in the range of 300 000 to 350 000 SCDs annually
14). The variation is based, in part, on the inclusion criteria
sed in individual studies. Overall, event rates in Europe are
imilar to those in the United States (3), with significant
eographic variations reported.
The temporal definition of SCD strongly influences
pidemiological data (15). The proportion of all natural
eaths due to SCD is 13% when a definition of 1 h from
nset of symptoms is used. In contrast, the community-wide
tudy in Maastricht, the Netherlands, reported that 18.5%
able 3. Inconsistencies Between ACC/AHA/ESC Guidelines fo
he Prevention of SCD and Other Published ACC/AHA and ES
revention to Reduce Total Mortality by a Reduction in SCD
Group Addressed in
Recommendation
Guideline and Class of
2005 ACC/AHA
HF 2005 ESC HF
2004 ACC
STEM
VD d/t MI, LVEF 30% or
less, NYHA II, III
Class I; LOE: B Class I; LOE: A Class IIa; L
VD d/t MI, LVEF 30% to
35%, NYHA II, III
Class IIa; LOE: B Class I; LOE: A N/A
VD d/t MI, LVEF 30% to
40%, NSVT, positive EP
study
N/A N/A Class I; LO
VD d/t MI, LVEF 30% or
less, NYHA I
Class IIa; LOE: B N/A N/A
VD d/t MI, LVEF 31% to
35% or less, NYHA I
N/A N/A N/A
ICM, LVEF 30% or less,
NYHA II, III
Class I; LOE: B Class I; LOE: A N/A
ICM, LVEF 30% to 35%,
NYHA II, III
Class IIa; LOE: B Class I; LOE: A N/A
ICM, LVEF 30% or less,
NYHA I
Class IIb; LOE: C N/A N/A
ICM, LVEF 31% to 35%
or less, NYHA I
N/A N/A N/A
For an explanation of Class Recommendation and Level of Evidence, see Table 2.
ACC/AHA HF  ACC/AHA 2005 Guideline Update for the Diagnosis and M
ACC/AHA/NASPE 2002 Guidelines Update for Implantation of Cardiac Pacema
or the Management of Patients With ST-Elevation Myocardial Infarction (2); EP 
f Chronic Heart Failure (5); LOE  level of evidence; LVD d/t MI  left ventricula
/A  populations not addressed; NICM  nonischemic cardiomyopathy; NSVT 
lass; SCD  sudden cardiac death; VA  ventricular arrhythmias.f all deaths were SCD, using a 24-h definition (16). The bpplication of a 24-h definition of SCD increases the
raction of all natural deaths falling into the “sudden”
ategory but reduces the proportion of all sudden natural
eaths that are due to cardiac causes (15).
Approximately 50% of all CHD deaths are sudden and
nexpected, occurring shortly (instantaneous to 1 h) after
he onset of a change in clinical status, with some geograph-
cal variation in the fraction of coronary deaths that are
udden (17). The decreasing age-adjusted CHD mortality
oes not imply a decrease in absolute numbers of cardiac or
CDs (18,19) because of the growth and aging of the
nited States and European populations and the increasing
revalence of chronic heart disease (20).
opulation Subgroups and Risk Prediction
Three factors affect the ability to identify subjects and
opulation subgroups at risk and consideration of strategies
or prevention of SCD:
The absolute numbers and event rates (incidence) among
population subgroups (Fig. 1)
The clinical subgroups in which SCDs occur
The time-dependence of risk (14).
The overall incidence of SCD in the United States is 1 to
/1000 population (0.1% to 0.2%) per year, with some
ariations in estimates based on differences in various
ources of data. This large population base includes those
ictims whose SCDs occur as a first cardiac event, as well as
hose whose SCDs can be predicted with greater accuracy
Management of Patients With Ventricular Arrhythmias and
uidelines With Respect to ICD Therapy for Primary
mendation With Level of Evidence* for Each Group
2002 ACC/AHA/NASPE
PM and ICD
Comment From the ACC/AHA/ESC VA
and SCD Guidelines
Class IIa; LOE: B VA and SCD has combined all trials that
enrolled patients with LVD d/t MI into one
recommendation, Class I; LOE: AN/A
Class IIb; LOE: B
N/A VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with LVD
d/t MI and NYHA functional class I into one
recommendation, Class IIa; LOE: B
N/A
N/A VA and SCD has combined all trials of NICM,
NYHA II, III into one recommendation, Class
I; LOE: BN/A
N/A VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with
NICM and NYHA functional class I into one
recommendation, Class IIb; LOE: B.
N/A
rther discussion, please see the Introduction.
ent of Chronic Heart Failure in the Adult (6); ACC/AHA/NASPE PM and ICD
d Antiarrhythmia Devices (1); ACC/AHA STEMI ACC/AHA 2004 Guidelines
ophysiological; ESC HF  ESC 2005 Guidelines for the Diagnosis and Treatment
unction due to prior myocardial infarction; LVEF  left ventricular ejection fraction;
ustained ventricular tachycardia; NYHA  New York Heart Association functionalr the
C G
Recom
/AHA
I
OE: B
E: B
For fu
anagem
kers an
electr
r dysfecause they are included in higher risk subgroups (Fig. 1).
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Classification by Clinical Presentation Reference
emodynamically stable Asymptomatic The absence of symptoms that could result from an arrhythmia. (7)
Minimal symptoms,
e.g., palpitations
Patient reports palpitations felt in either the chest, throat, or neck as described by
the following:
 Heartbeat sensations that feel like pounding or racing
 An unpleasant awareness of heartbeat
 Feeling skipped beats or a pause
(7)
emodynamically unstable Presyncope Patient reports presyncope as described by the following:
 Dizziness
 Lightheadedness
 Feeling faint
 “Graying out”
(7)
Syncope Sudden loss of consciousness with loss of postural tone, not related to anesthesia,
with spontaneous recovery as reported by the patient or observer. Patient may
experience syncope when supine.
(7)
Sudden cardiac
death
Death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia
occurring within an hour of the onset of symptoms.
(7a)
Sudden cardiac
arrest
Death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia
occurring within an hour of the onset of symptoms, in whom medical
intervention (e.g., defibrillation) reverses the event.
(7)
Classification by Electrocardiography
onsustained VT Three or more beats in duration, terminating spontaneously in less than 30 s. (7)
VT is a cardiac arrhythmia of three or more consecutive complexes in duration
emanating from the ventricles at a rate of greater than 100 bpm (cycle length
less than 600 ms)
Monomorphic Nonsustained VT with a single QRS morphology. (7)
Polymorphic Nonsustained VT with a changing QRS morphology at cycle length between 600
and 180 ms.
(7)
ustained VT VT greater than 30 s in duration and/or requiring termination due to
hemodynamic compromise in less than 30 s.
(7)
Monomorphic Sustained VT with a stable single QRS morphology. (7)
Polymorphic Sustained VT with a changing or multiform QRS morphology at cycle length
between 600 and 180 ms.
(7)
undle-branch re-entrant tachycardia VT due to re-entry involving the His-Purkinje system, usually with LBBB
morphology; this usually occurs in the setting of cardiomyopathy.
(7)
idirectional VT VT with a beat-to-beat alternans in the QRS frontal plane axis, often associated
with digitalis toxicity.
(7)
orsades de pointes Characterized by VT associated with a long QT or QTc, and
electrocardiographically characterized by twisting of the peaks of the QRS
complexes around the isoelectric line during the arrhythmia:
 “Typical,” initiated following “short-long-short” coupling intervals.
 Short coupled variant initiated by normal-short coupling.
(7)
entricular flutter A regular (cycle length variability 30 ms or less) ventricular arrhythmia
approximately 300 bpm (cycle length—200 ms) with a monomorphic
appearance; no isoelectric interval between successive QRS complexes.
(7)
entricular fibrillation Rapid, usually more than 300 bpm/200 ms (cycle length 180 ms or less), grossly
irregular ventricular rhythm with marked variability in QRS cycle length,
morphology, and amplitude.
(7)
Classification by Disease Entity
hronic coronary heart disease
eart failure
ongenital heart disease
eurological disorders
tructurally normal hearts
udden infant death syndrome
ardiomyopathies
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular
cardiomyopathy
BBB  left bundle-branch block; VT  ventricular tachycardia.
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cation of more specific subgroups. However, the corre-
ponding absolute number of deaths becomes progressively
maller as the subgroups become more focused, limiting the
otential impact of interventions to a much smaller fraction
f the total population (21).
II. CLINICAL PRESENTATIONS
F PATIENTS WITH VENTRICULAR
RRHYTHMIAS AND SUDDEN CARDIAC DEATH
entricular arrhythmias can occur in individuals with or
ithout cardiac disorders. There is a great deal of overlap
etween clinical presentations (Table 5) and severity and
ype of heart disease. For example, stable and well-tolerated
T can occur in the individual with previous myocardial
nfarction (MI) and impaired ventricular function. The
rognosis and management are individualized according to
ymptom burden and severity of underlying heart disease in
ddition to the clinical presentation.
V. RESTING ELECTROCARDIOGRAPHY
ecommendations
lass I
Resting 12-lead electrocardiogram (ECG) is indi-
cated in all patients who are evaluated for ventricular
arrhythmias. (Level of Evidence: A)
A standard resting 12-lead ECG allows not only identifi-
ation of various congenital abnormalities associated with
entricular arrhythmias and SCD (e.g., long QT syndrome
LQTS], short QT syndrome, Brugada syndrome, arrhythmo-
enic right ventricular [RV] cardiomyopathy) but also identi-
cation of various other ECG parameters, such as those due to
lectrolyte disturbances, or evidence suggesting underlying
igure 1. Absolute numbers of events and event rates of SCD in the gener
o unselected population age greater than or equal to 35 y, and high-risk s
rials that include specific subpopulations of patients are shown in the right
ASH, Cardiac Arrest Study Hamburg; CIDS  Canadian Implan
ADIT Multicenter Automatic Defibrillator Implantation Trial; MI
CD-HeFT  Sudden Cardiac Death in Heart Failure Trial. Modified w
unction, and time-dependence of risk. Circulation 1992;85:I2–10.tructural disease such as bundle-branch block, atrioventricularAV) block, ventricular hypertrophy, and Q waves indicative of
schemic heart disease or infiltrative cardiomyopathy.
. EXERCISE TESTING
ecommendations
lass I
. Exercise testing is recommended in adult patients
with ventricular arrhythmias who have an interme-
diate or greater probability of having CHD by age,
gender, and symptoms* to provoke ischemic
changes or ventricular arrhythmias. (Level of Evi-
dence: B) *See Table 4 in the ACC/AHA 2002 Guide-
line Update for Exercise Testing (22) for further
explanation of CHD probability.
. Exercise testing, regardless of age, is useful in
patients with known or suspected exercise-induced
ventricular arrhythmias, including catecholaminer-
gic VT to provoke the arrhythmia, achieve a diagnosis,
ulation and in specific subpopulations over 1 y. General population refers
ups to those with multiple risk factors for a first coronary event. Clinical
f the figure. AVID  Antiarrhythmics Versus Implantable Defibrillators;
Defibrillator Study; EF  ejection fraction; HF  heart failure;
ardial infarction; MUSTTMulticenter UnSustained Tachycardia Trial;
rmission from Myerburg RJ, Kessler KM, Castellanos A. SCD. Structure,
able 5. Clinical Presentations of Patients With Ventricular
rrhythmias and Sudden Cardiac Death
Asymptomatic individuals with or without electrocardiographic
abnormalities
Persons with symptoms potentially attributable to ventricular
arrhythmias
Œ Palpitations
Œ Dyspnea
Œ Chest pain
Œ Syncope and presyncope
Ventricular tachycardia that is hemodynamically stable
Ventricular tachycardia that is not hemodynamically stable
Cardiac arrest
Œ Asystolic (sinus arrest, atrioventricular block)
Œ Ventricular tachycardia
Œ Ventricular fibrillational pop
ubgro
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(Level of Evidence: B)
lass IIa
Exercise testing can be useful in evaluating response
to medical or ablation therapy in patients with known
exercise-induced ventricular arrhythmias. (Level of
Evidence: B)
lass IIb
. Exercise testing may be useful in patients with ventric-
ular arrhythmias and a low probability of CHD by age,
gender, and symptoms.* (Level of Evidence: C) *See Table
4 in the ACC/AHA 2002 Guideline Update for Exercise
Testing (22) for further explanation of CHD probability.
. Exercise testing may be useful in the investigation of
isolated premature ventricular complexes (PVCs) in
middle-aged or older patients without other evidence
of CHD. (Level of Evidence: C)
lass III
See Table 1 in the ACC/AHA 2002 Guideline Up-
date for Exercise Testing (22) for contraindications.
(Level of Evidence: B)
Exercise ECG is commonly used in the evaluation of
atients with ventricular arrhythmias. Its most common appli-
ation is for detection of silent ischemia in patients suspected of
aving underlying CHD (22). In patients with known or silent
HD or cardiomyopathies, the presence of frequent PVCs
uring or after exercise has been associated with greater risk for
erious cardiovascular events but not specifically to SCD
23–25). However, exercise-induced PVCs in apparently nor-
al individuals should not be used to dictate therapy unless
ssociated with documented ischemia or sustained VT.
I. AMBULATORY ELECTROCARDIOGRAPHY
ecommendations
lass I
. Ambulatory ECG is indicated when there is a need
to clarify the diagnosis by detecting arrhythmias,
QT-interval changes, T-wave alternans, or ST
changes, to evaluate risk, or to judge therapy. (Level
of Evidence: A)
. Event monitors are indicated when symptoms are
sporadic to establish whether they are caused by
transient arrhythmias. (Level of Evidence: B)
. Implantable recorders are useful in patients with
sporadic symptoms suspected to be related to ar-
rhythmias such as syncope when a symptom–rhythm
correlation cannot be established by conventional
diagnostic techniques. (Level of Evidence: B)
The use of continuous or intermittent ambulatory record-
ng techniques can be very helpful in diagnosing a suspectedrrhythmia, establishing its frequency and relating symp-
oms to the presence of the arrhythmia. Silent myocardial
schemic episodes may also be detected.
II. ELECTROCARDIOGRAPHIC
ECHNIQUES AND MEASUREMENTS
ecommendations
lass IIa
It is reasonable to use T-wave alternans for improv-
ing the diagnosis and risk stratification of patients
with ventricular arrhythmias or who are at risk for
developing life-threatening ventricular arrhythmias.
(Level of Evidence: A)
lass IIb
ECG techniques such as signal-averaged ECG, heart
rate variability, baroflex sensitivity, and heart rate
turbulence may be useful for improving the diagnosis
and risk stratification of patients with ventricular
arrhythmias or who are at risk of developing life-
threatening ventricular arrhythmias. (Level of Evi-
dence: B)
ICD trials, especially Multicenter Automatic Defibrilla-
or Implantation Trial (MADIT) II, have highlighted the
eed to develop novel tools in order to identify patients at
ighest risk of ventricular arrhythmias and SCD. Numerous
odalities exist at present for assessing this risk but only 2
re currently approved by the U.S. Food and Drug Admin-
stration: signal-averaged ECG and T-wave alternans.
owever, heart rate variability and baroflex sensitivity also
how considerable promise.
III. LEFT VENTRICULAR FUNCTION AND IMAGING
ecommendations
lass I
. Echocardiography is recommended in patients with
ventricular arrhythmias who are suspected of having
structural heart disease. (Level of Evidence: B)
. Echocardiography is recommended for the subset of
patients at high risk for development of serious
ventricular arrhythmias or SCD, such as those with
dilated, hypertrophic, or RV cardiomyopathies,
acute MI survivors, or relatives of patients with
inherited disorders associated with SCD. (Level of
Evidence: B)
. Exercise testing with an imaging modality (echocar-
diography or nuclear perfusion (single-photon emis-
sion computed tomography [SPECT]) is recom-
mended to detect silent ischemia in patients with
ventricular arrhythmias who have an intermediate
probability of having CHD by age, symptoms, and
gender and in whom ECG assessment is less reliable
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1-mm ST-segment depression at rest, Wolff-
Parkinson-White syndrome, or left bundle-branch
block. (Level of Evidence: B)
. Pharmacological stress testing with an imaging mo-
dality (echocardiography or myocardial perfusion
SPECT) is recommended to detect silent ischemia
in patients with ventricular arrhythmias who have an
intermediate probability of having CHD by age,
symptoms, and gender and are physically unable to
perform a symptom-limited exercise test. (Level of
Evidence: B)
lass IIa
. Magnetic resonance imaging (MRI), cardiac computed
tomography (CT), or radionuclide angiography can be
useful in patients with ventricular arrhythmias when
echocardiography does not provide accurate assess-
ment of LV and RV function and/or evaluation of
structural changes. (Level of Evidence: B)
. Coronary angiography can be useful in establishing
or excluding the presence of significant obstructive
CHD in patients with life-threatening ventricular
arrhythmias or in survivors of SCD, who have an
intermediate or greater probability of having CHD
by age, symptoms, and gender. (Level of Evidence: C)
. LV imaging can be useful in patients undergoing
biventricular pacing. (Level of Evidence: C)
. Echocardiography
chocardiography is the imaging technique most commonly
sed because it is inexpensive in comparison with other
echniques such as MRI and cardiac CT, is readily available,
nd provides accurate diagnosis of myocardial, valvular, and
ongenital heart disorders associated with ventricular ar-
hythmias and SCD (26,27) (Table 6). In addition, LV
ystolic function and regional wall motion can be evaluated,
nd in a majority of patients, EF can be determined (28).
. Radionuclide Techniques
yocardial perfusion SPECT using exercise or pharmaco-
ogical agents is applicable for a selected group of patients
uspected of having ventricular arrhythmias triggered by
schemia and who are unable to exercise or have resting
able 6. Conditions Associated With Ventricular Arrhythmias
hat Can Be Diagnosed With Echocardiography
Disease Entity Diagnostic Accuracy
ilated cardiomyopathy High
schemic cardiomyopathy High
ypertension with moderate to severe LVH High
ypertrophic cardiomyopathy High
alvular heart disease High
RVC Moderate
rugada syndrome PoorRVC  arrhythmogenic right ventricular cardiomyopathy; LVH  left ventricular
ypertrophy.CG abnormalities that limit the accuracy of ECG for
schemia detection.
. Coronary Angiography
n patients with life-threatening ventricular arrhythmias or
n survivors of SCD, coronary angiography plays an impor-
ant diagnostic role in establishing or excluding the presence
f significant obstructive CHD.
X. ELECTROPHYSIOLOGICAL TESTING
lectrophysiological (EP) testing with intracardiac record-
ng and electrical stimulation at baseline and with drugs has
een used for arrhythmia assessment and risk stratification
or SCD. EP testing is used to document inducibility of VT,
uide ablation, evaluate drug effects, assess the risks of
ecurrent VT or SCD, evaluate loss of consciousness in
elected patients with arrhythmias suspected as a cause, and
ssess the indications for ICD therapy (29–32).
. Electrophysiological Testing
n Patients With Coronary Heart Disease
ecommendations
lass I
. EP testing is recommended for diagnostic evaluation
of patients with remote MI with symptoms suggestive
of ventricular tachyarrhythmias including palpitations,
presyncope, and syncope. (Level of Evidence: B)
. EP testing is recommended in patients with CHD to
guide and assess efficacy of VT ablation. (Level of
Evidence: B)
. EP testing is useful in patients with CHD for the
diagnostic evaluation of wide-QRS-complex tachy-
cardias of unclear mechanism. (Level of Evidence: C)
lass IIa
EP testing is reasonable for risk stratification in patients
with remote MI, nonsustained VT, and LVEF equal to
or less than 40%. (Level of Evidence: B)
Drug testing for assessing antiarrhythmic drug efficacy has
argely been abandoned. The prognostic value of inducible
entricular flutter and fibrillation is still controversial. Limited
ata on the prognostic value of inducible ventricular flutter
uggest that it may be an important end point (33,34).
. Electrophysiological Testing in Patients With Syncope
ecommendations
lass I
EP testing is recommended in patients with syncope
of unknown cause with impaired LV function or
structural heart disease. (Level of Evidence: B)
Cu
c
t
w
t
s
a
m
p
c
s
s
X
U
d
S
t
c
i
a
r
s
h
s
l
m
d
a
a
A
T
b
s
h
a
o
B
T
c
o
l
r
d
C
n
p
t
a
s
X
A
A
(
b
(
A
T
f
B
f
s
d
B
C
R
F
I
T
(
r
r
i
c
t
X
E
S
m
p
e
c
d
f
i
e
s
t
l
e
w
V
p
1075JACC Vol. 48, No. 5, 2006 Zipes et al.
September 5, 2006:1064–1108 ACC/AHA/ESC Practice Guidelines—Executive Summarylass IIa
EP testing can be useful in patients with syncope
when bradyarrhythmias or tachyarrhythmias are sus-
pected and in whom noninvasive diagnostic studies
are not conclusive. (Level of Evidence: B)
Syncope is a transient symptom that may be caused by an
nderlying rhythm disorder with or without an associated
ardiac disease. EP testing is used to document or exclude
he arrhythmic cause of syncope. It is most useful in patients
ith CHD and LV dysfunction. EP testing is usually not
he first evaluation step but rather complementary to a full
yncope work-up. Lack of correlation between symptoms
nd a documented arrhythmia elicited during EP testing
ay lead to overinterpretation or underinterpretation of the
redictive value of the results. Transient drug effects that
an provoke syncope may remain undetected. Other causes
uch as a neurological etiology need to be considered in
ome patients.
. VALUE OF ANTIARRHYTHMIC DRUGS
se of antiarrhythmic drugs in the acute setting is
escribed in Section XIII on Acute Management of
pecific Arrhythmias.
The available antiarrhythmic drugs can be classified by
he Vaughan Williams 4-level schema (type I: fast sodium
hannel blockers, type II: beta blockers, type III: repolar-
zation potassium current blockers, type IV: calcium channel
ntagonists) (35), or by the more mechanistic and clinically
elevant Sicilian Gambit (36). The Vaughan Williams
chema is somewhat outdated because antiarrhythmic drugs
ave complex actions that do not easily fit into 1 of the 4
pecified classes of drug effects. This classification is of
imited usefulness when choosing an antiarrhythmic drug to
anage a specific arrhythmia. The Sicilian Gambit, intro-
uced in 1991, was an attempt to provide a classification of
ntiarrhythmic drugs based on their mechanism of action
nd on arrhythmogenic mechanisms.
. Beta Blockers
hese drugs are effective in suppressing ventricular ectopic
eats and arrhythmias as well as reducing SCD in a
pectrum of cardiac disorders in patients with and without
eart failure (HF). Beta blockers are safe and effective
ntiarrhythmic agents that can be considered the mainstay
f antiarrhythmic drug therapy (37,38).
. Amiodarone and Sotalol
he overall long-term survival benefit from amiodarone is
ontroversial, with most studies showing no clear advantage
ver placebo. A few studies and one meta-analysis of several
arge studies have shown reduction in SCD using amioda-
one for LV dysfunction due to prior MI and nonischemic
ilated cardiomyopathy (DCM) (39–41), but the Sudden
ardiac Death in Heart Failure Trial (SCD-HeFT) showed oo survival benefit from amiodarone when compared with
lacebo (8,42).
Sotalol, like amiodarone, is effective in suppressing ven-
ricular arrhythmias, but it has greater proarrhythmic effects
nd has not been shown to provide a clear increase in
urvival.
I. SPECIAL CONSIDERATIONS WHERE
NTIARRHYTHMIC DRUGS MAY BE INDICATED
miodarone therapy may be considered in special situations
43); secondary subset analyses indicate possible survival
enefit when amiodarone is combined with beta blockers
44,45).
. Patients With Ventricular
achyarrhythmias Who Do Not Meet Criteria
or an Implantable Cardioverter-Defibrillator
eta blockers are the first-line therapy, but if this therapy at
ull therapeutic dose is not effective, then amiodarone or
otalol can be tried with monitoring for adverse effects
uring administration.
. Patients With Implantable
ardioverter-Defibrillators Who Have
ecurrent Ventricular Tachycardia/Ventricular
ibrillation With Frequent Appropriate
mplantable Cardioverter-Defibrillator Firing
his scenario, in its extreme, has been called defibrillator
tachycardia) storm, and it requires the addition of antiar-
hythmic drugs and/or catheter ablation for control of the
ecurrent VT and associated ICD shocks. Sotalol is effective
n suppressing atrial and ventricular arrhythmias (46), the
ombination of beta blockers and amiodarone is an alterna-
ive approach. Intravenous amiodarone has been useful.
II. IMPLANTABLE AND
XTERNAL CARDIOVERTER DEVICES
everal prospective multicenter clinical trials have docu-
ented improved survival with ICD therapy in high-risk
atients with LV dysfunction due to prior MI and nonisch-
mic cardiomyopathy (8,47–53) (Figure 2). ICD therapy
ompared with conventional or traditional antiarrhythmic
rug therapy has been associated with mortality reductions
rom 23% to 55% depending on the risk group participating
n the trial, with the improvement in survival due almost
xclusively to a reduction in SCD. The trials may be
ubcategorized into 2 types: primary prevention (prophylac-
ic) trials in which the subjects have not experienced a
ife-threatening ventricular arrhythmia or a symptomatic
quivalent and secondary prevention trials involving subjects
ho have had an abortive cardiac arrest, a life-threatening
T, or unexplained syncope with work-up suggesting a high
robability that a ventricular tachyarrhythmia was the cause
f the syncope.
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he automated external defibrillator (AED) saves lives
hen external defibrillation can be rendered within minutes
f onset of VF. The AED represents an efficient method of
elivering defibrillation to persons experiencing out-of-
ospital cardiac arrest, and its use by both traditional and
ontraditional first responders appears to be safe and effec-
ive (54,55). Appropriate device location to reduce time
elay after onset of cardiac arrest is critical. Federal, state,
nd community efforts have been effective in placing AEDs
n schools, sporting events, high-density residential sites,
nd airports as well as on airplanes and in police and fire
epartment vehicles (56–58).
. Ablation
ecommendations
lass I
. Ablation is indicated in patients who are otherwise at
low risk for SCD and have sustained predominantly
monomorphic VT that is drug resistant, who are drug
intolerant, or who do not wish long-term drug ther-
apy. (Level of Evidence: C)
. Ablation is indicated in patients with bundle-branch
igure 2. Major implantable cardioverter-defibrillator (ICD) trials. Hazar
rom any cause in the ICD group compared with the non-ICD group. *In
ames, see Appendix 3. CABG  coronary artery bypass graft surgery; EP
entricular ejection fraction; MI  myocardial infarction; N  number
entricular tachycardia; PVCs  premature ventricular complexes; SAECreentrant VT. (Level of Evidence: C). Ablation is indicated as adjunctive therapy in patients
with an ICD who are receiving multiple shocks as a
result of sustained VT that is not manageable by
reprogramming or changing drug therapy or who do
not wish long-term drug therapy (59,60). (Level of
Evidence: C)
. Ablation is indicated in patients with Wolff-
Parkinson-White syndrome resuscitated from sudden
cardiac arrest due to atrial fibrillation and rapid
conduction over the accessory pathway causing VF
(61). (Level of Evidence: B)
lass IIa
. Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have symptomatic
nonsustained monomorphic VT that is drug resis-
tant, who are drug intolerant, or who do not wish
long-term drug therapy. (Level of Evidence: C)
. Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have frequent
symptomatic predominantly monomorphic PVCs
that are drug resistant, who are drug intolerant, or
who do not wish long-term drug therapy. (Level of
Evidence: C)
. Ablation can be useful in symptomatic patients with
os (vertical line) and 95% confidence intervals (horizontal lines) for death
s only ICD and amiodarone patients from CASH. For expansion of trial
ctrophysiological study; LVD  left ventricular dysfunction; LVEF  left
tients; NICM  nonischemic cardiomyopathy; NSVT  nonsustained
signal-averaged electrocardiogram.d rati
clude
 eleWolff-Parkinson-White syndrome who have acces-
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ms in duration (61). (Level of Evidence: B)
lass IIb
. Ablation of Purkinje fiber potentials may be consid-
ered in patients with ventricular arrhythmia storm
consistently provoked by PVCs of similar morphol-
ogy (62). (Level of Evidence: C)
. Ablation of asymptomatic PVCs may be considered
when the PVCs are very frequent to avoid or treat
tachycardia-induced cardiomyopathy (63). (Level of
Evidence: C)
lass III
Ablation of asymptomatic relatively infrequent PVCs
is not indicated. (Level of Evidence: C)
The specific application of radiofrequency ablation to VT
as evolved as the technology has developed. Radiofrequency
blation can be applied in the treatment of VT in patients with
schemic disease, cardiomyopathy, bundle-branch re-entry,
nd various forms of idiopathic VT (64–76).
. Antiarrhythmic Surgery
n patients with recurrent VT refractory to drugs, implanted
efibrillators, and radiofrequency catheter ablation, direct
urgical ablation or resection of the arrhythmogenic focus is
n approach that continues to be used in experienced
enters. Surgery requires accurate preoperative and intraop-
rative mapping to determine the site or sites of the
achycardia. Some centers use a scar-based approach to
esecting arrhythmogenic sites.
Left cervicothoracic sympathetic ganglionectomy is asso-
iated with reduction in the frequency of arrhythmogenic
yncope in the congenital LQTS and may be useful as
djunctive therapy in high-risk patients with long QT who
ave recurrent syncope and/or aborted cardiac arrest despite
ombined ICD and beta-blocker therapy or in patients with
ong QT who cannot tolerate beta blockers (77).
. Revascularization for Arrhythmia Management
review of coronary revascularization studies reveals im-
roved survival and reduction in SCD during long-term
ollow-up (78,79). If obstructive CHD is complicated by
entricular arrhythmias, especially in patients with left main
nd proximal left anterior descending coronary artery dis-
ase, there is a reasonable likelihood that revascularization
ill reduce the frequency and complexity of the arrhythmias
nd, in some patients, will eliminate such arrhythmias.
III. ACUTE MANAGEMENT
F SPECIFIC ARRHYTHMIAS
. Management of Cardiac Arrest
ardiac arrest is characterized by an abrupt loss of
ffective blood flow, sufficient to cause immediate loss ofonsciousness, leading immediately to death if untreated.
he most common electrical mechanisms for cardiac
rrest are VF and pulseless VT (see Section 4 in the
ull-text guidelines), but substantial numbers of cardiac
rrests begin as severe bradyarrhythmias, asystole, or
ulseless electrical activity.
ecommendations
lass I
. After establishing the presence of definite, sus-
pected, or impending cardiac arrest, the first priority
should be activation of a response team capable of
identifying the specific mechanism and carrying out
prompt intervention. (Level of Evidence: B)
. Cardiopulmonary resuscitation (CPR) should be im-
plemented immediately after contacting a response
team. (Level of Evidence: A)
. In an out-of-hospital setting, if an AED is available,
it should be applied immediately and shock therapy
administered according to the algorithms contained
in the documents on CPR (80,81) developed by the
American Heart Association (AHA) in association
with the International Liaison Committee on Re-
suscitation (ILCOR) and/or the European Resusci-
tation Council (ERC). (Level of Evidence: C)
. For victims with ventricular tachyarrhythmic mech-
anisms of cardiac arrest, when recurrences occur
after a maximally defibrillating shock (generally 360
J for monophasic defibrillators), intravenous amio-
darone should be the preferred antiarrhythmic drug
for attempting a stable rhythm after further defibril-
lations. (Level of Evidence: B)
. For recurrent ventricular tachyarrhythmias or non-
tachyarrhythmic mechanisms of cardiac arrest, it is
recommended to follow the algorithms contained in
the documents on CPR (80,81) developed by the
AHA in association with ILCOR and/or the ERC.
(Level of Evidence: C)
. Reversible causes and factors contributing to cardiac
arrest should be managed during advanced life sup-
port, including management of hypoxia, electrolyte
disturbances, mechanical factors, and volume deple-
tion. (Level of Evidence: C)
lass IIa
For response times greater than or equal to 5 min, a
brief (less than 90 to 180 s) period of CPR is
reasonable prior to attempting defibrillation. (Level
of Evidence: B)
lass IIb
A single precordial thump may be considered by
healthcare professional providers when responding to
a witnessed cardiac arrest. (Level of Evidence: C)
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elated to electrical methods for control of tachyarrhyth-
ias, led to the generation of complex protocols to guide
esponders. These documents, published by the AHA (80)
nd the ERC (81), cover the broad expanse of clinical
ircumstances and considerations of mechanisms. They
rovide management information, stratified for special cir-
umstances such as age of the victim (from infancy to the
lderly), pathophysiological status, and survival probabili-
ies. The response algorithms to these various circumstances
re complex and the reader is referred to the source
ocuments for details (80,81). As management guidelines,
hese documents are classified as Level of Evidence C, but
hey are derived from a combination of varied studies and
pinion that range from Levels of Evidence A, B, or C.
bbreviated versions for tachyarrhythmias and nontachya-
rhythmic mechanisms are shown in Figure 3 in the full-text
uidelines.
. Arrhythmias Associated
ith Acute Coronary Syndromes
he incidence of VF (occurring within 48 h of the onset of
he acute coronary syndrome [ACS]) may be decreasing
wing to aggressive revascularization limiting infarct size
nd to increased beta-blocker use (82). VF occurring early in
he ACS has been associated with an increase in hospital
ortality but not with increased long-term mortality (83).
rophylaxis with lidocaine may reduce the incidence of VF
n the ACS but appears to be associated with increased
ortality, likely owing to bradycardia, and this treatment
as largely been abandoned (84). Use of prophylactic beta
lockers in the setting of acute MI reduces the incidence of
F, and this practice is encouraged when appropriate.
imilarly, correction of hypomagnesemia and hypokalemia
s encouraged because of the potential contribution of
lectrolyte disturbances to VF (85).
. Ventricular Tachycardia Associated
ith Low Troponin Myocardial Infarction
ecommendations
lass I
Patients presenting with sustained VT in whom
low-level elevations in cardiac biomarkers of myocyte
injury/necrosis are documented should be treated
similarly to patients who have sustained VT and in
whom no biomarker rise is documented. (Level of
Evidence: C)
. Sustained Monomorphic Ventricular Tachycardia
ecommendations
lass I
. Wide-QRS tachycardia should be presumed to be
VT if the diagnosis is unclear. (Level of Evidence: C) i. Direct-current cardioversion with appropriate seda-
tion is recommended at any point in the treatment
cascade in patients with suspected sustained mono-
morphic VT with hemodynamic compromise. (Level
of Evidence: C)
lass IIa
. Intravenous procainamide (or ajmaline in some Eu-
ropean countries) is reasonable for initial treatment
of patients with stable sustained monomorphic VT.
(Level of Evidence: B)
. Intravenous amiodarone is reasonable for patients
with sustained monomorphic VT that is hemody-
namically unstable, refractory to conversion with
countershock, or recurrent despite procainamide or
other agents. (Level of Evidence: C)
. Transvenous catheter pace termination can be useful
to treat patients with sustained monomorphic VT
that is refractory to cardioversion or is frequently
recurrent despite antiarrhythmic medication. (Level
of Evidence: C)
lass IIb
Intravenous lidocaine might be reasonable for initial
treatment of patients with stable sustained mono-
morphic VT specifically associated with acute myo-
cardial ischemia or infarction. (Level of Evidence: C)
lass III
Calcium channel blockers such as verapamil and
diltiazem should not be used in patients to terminate
wide-QRS-complex tachycardia of unknown origin,
especially in patients with a history of myocardial
dysfunction. (Level of Evidence: C)
Correction of potentially causative or aggravating condi-
ions such as hypokalemia and ischemia is an early priority.
imely termination is usually desirable even if VT is well
olerated. This can be achieved with cardioversion, antiar-
hythmic medications, or pacing techniques.
Initial treatment often includes the administration of
ntravenous antiarrhythmic medication. The advantages
nclude the lack of necessity for anesthesia and ready
vailability.
Intravenous amiodarone is not ideal for early conversion
f stable monomorphic VT. Intravenous procainamide is
ore appropriate when early slowing of the VT rate and
ermination of monomorphic VT are desired (86,87). Close
onitoring of blood pressure and cardiovascular status is
ecommended in the presence of congestive HF or severe
V dysfunction as intravenous procainamide can cause
ransient hypotension (88). Lidocaine is effective when VT
s thought to be related to myocardial ischemia (89,90).
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ecommendations
lass IIa
Intravenous amiodarone, beta blockers, and intrave-
nous procainamide (or sotalol or ajmaline in Europe)
can be useful for treating repetitive monomorphic VT
in the context of coronary disease (91) and idiopathic
VT. (Level of Evidence: C)
Repetitive monomorphic VT is characterized electrocar-
iographically by frequent ventricular ectopy and salvos of
onsustained ventricular tachycardia (NSVT) with inter-
ening sinus rhythm. It typically occurs at rest and is
elf-terminating, although the arrhythmia can be present for
uch of the time (92). Although this terminology can refer
o mechanistically diverse arrhythmias, it generally refers to
diopathic VT, most frequently the RV outflow type (93–
5). This tachycardia can cause palpitations or, rarely,
achycardia-related cardiomyopathy (96). Many patients
ave no symptoms related to the arrhythmia. In some
atients, tachycardia is provoked by exercise (97). An
lectrocardiographically similar presentation is less frequent
n patients with structural heart disease and, specifically,
revious MI (91).
Beta-blocking agents or calcium channel blockers are
ften effective. Ablation is generally successful in problem-
tic RV outflow tachycardia (98).
. Polymorphic Ventricular Tachycardia
ecommendations
lass I
. Direct current cardioversion with appropriate seda-
tion as necessary is recommended for patients with
sustained polymorphic VT with hemodynamic com-
promise and is reasonable at any point in the treat-
ment cascade. (Level of Evidence: B)
. Intravenous beta blockers are useful for patients
with recurrent polymorphic VT especially if isch-
emia is suspected or cannot be excluded. (Level of
Evidence: B)
. Intravenous loading with amiodarone is useful for
patients with recurrent polymorphic VT in the ab-
sence of abnormal repolarization related to congen-
ital or acquired LQTS. (Level of Evidence: C)
. Urgent angiography with a view to revascularization
should be considered for patients with polymorphic
VT when myocardial ischemia cannot be excluded.
(Level of Evidence: C)
lass IIb
Intravenous lidocaine may be reasonable for treat-
ment of polymorphic VT specifically associated with
acute myocardial ischemia or infarction. (Level of
Evidence: C) dPolymorphic VT may be sustained, generally requiring
rgent electrical cardioversion or self-terminating with in-
erludes of sinus rhythm.
Intravenous beta blockers are useful in this context and
mprove mortality in the setting of recurrent polymorphic
T with acute MI (99). Intravenous loading with amioda-
one is also useful (80,81,100–102). Urgent coronary an-
iography should be considered in the setting or recurrent
olymorphic VT when ischemia is suspected or cannot be
xcluded (103).
. Torsades de Pointes
ecommendations
lass I
. Withdrawal of any offending drugs and correction of
electrolyte abnormalities are recommended in pa-
tients presenting with torsades de pointes. (Level of
Evidence: A)
. Acute and long-term pacing is recommended for
patients presenting with torsades de pointes due to
heart block and symptomatic bradycardia. (Level of
Evidence: A)
lass IIa
. Management with intravenous magnesium sulfate is
reasonable for patients who present with LQTS and
few episodes of torsades de pointes. Magnesium is
not likely to be effective in patients with a normal
QT interval. (Level of Evidence: B)
. Acute and long-term pacing is reasonable for pa-
tients who present with recurrent pause-dependent
torsades de pointes. (Level of Evidence: B)
. Beta blockade combined with pacing is reasonable
acute therapy for patients who present with torsades de
pointes and sinus bradycardia. (Level of Evidence: C)
. Isoproterenol is reasonable as temporary treatment
in acute patients who present with recurrent pause-
dependent torsades de pointes who do not have
congenital LQTS. (Level of Evidence: B)
lass IIb
. Potassium repletion to 4.5 to 5 mM/L may be
considered for patients who present with torsades de
pointes. (Level of Evidence: B)
. Intravenous lidocaine or oral mexiletine may be
considered in patients who present LQT3 and tor-
sades de pointes. (Level of Evidence: C)
Marked QT interval prolongation and the morphologi-
ally distinctive polymorphic VT torsades de pointes occur
n 3 common settings: congenital LQTS, a drug-associated
orm, and in patients with advanced conduction system
isease that has progressed to heart block.
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ecommendations
lass I
Revascularization and beta blockade followed by
intravenous antiarrhythmic drugs such as procain-
amide or amiodarone are recommended for patients
with recurrent or incessant polymorphic VT due to
acute myocardial ischemia. (Level of Evidence: C)
lass IIa
Intravenous amiodarone or procainamide followed by
VT ablation can be effective in the management of
patients with frequently recurring or incessant mono-
morphic VT. (Level of Evidence: B)
lass IIb
. Intravenous amiodarone and intravenous beta block-
ers separately or together may be reasonable in pa-
tients with VT storm. (Level of Evidence: C)
. Overdrive pacing or general anesthesia may be con-
sidered for patients with frequently recurring or
incessant VT. (Level of Evidence: C)
. Spinal cord modulation may be considered for some
patients with frequently recurring or incessant VT.
(Level of Evidence: C)
. Clinical Features
he syndrome of very frequent episodes of VT requiring
ardioversion has been termed “VT storm.”
Management guidelines for these syndromes rely on
necdotal evidence because they are rare, there are multiple
otential underlying mechanisms, and no randomized trials
ave been conducted.
Intravenous beta blockade should be considered for a
olymorphic VT storm as it is the single most effective
herapy. It is of utmost importance to try and understand
he substrate of incessant arrhythmias because if a diagnosis
s established, a targeted treatment may be possible.
IV. VENTRICULAR ARRHYTHMIA AND SUDDEN
ARDIAC DEATH RELATED TO SPECIFIC PATHOLOGY
. Left Ventricular Dysfunction
ue to Prior Myocardial Infarction
ecommendations
lass I
. Aggressive attempts should be made to treat HF
that may be present in some patients with LV
dysfunction due to prior MI and ventricular tachy-
arrhythmias. (Level of Evidence: C)
. Aggressive attempts should be made to treat myo-
cardial ischemia that may be present in some pa-tients with ventricular tachyarrhythmias. (Level of
Evidence: C)
. Coronary revascularization is indicated to reduce the
risk of SCD in patients with VF when direct, clear
evidence of acute myocardial ischemia is docu-
mented to immediately precede the onset of VF.
(Level of Evidence: B)
. If coronary revascularization cannot be carried out,
and there is evidence of prior MI and significant LV
dysfunction, the primary therapy of patients resus-
citated from VF should be the ICD in patients who
are receiving chronic optimal medical therapy and
those who have reasonable expectation of survival
with a good functional status for more than 1 y.
(Level of Evidence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who are
at least 40 d post-MI, have an LVEF less than or equal
to 30% to 40%, are NYHA functional class II or III, are
receiving chronic optimal medical therapy, and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evidence:
A) (See Section IA.)
. The ICD is effective therapy to reduce mortality by
a reduction in SCD in patients with LV dysfunction
due to prior MI who present with hemodynamically
unstable sustained VT, who are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
lass IIa
. Implantation of an ICD is reasonable in patients
with LV dysfunction due to prior MI who are at least
40 d post-MI, have an LVEF of less than or equal to
30% to 35%, are NYHA functional class I on chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: B) (See Section
IA.)
. Amiodarone, often in combination with beta block-
ers, can be useful for patients with LV dysfunction
due to prior MI and symptoms due to VT unrespon-
sive to beta-adrenergicblocking agents. (Level of
Evidence: B)
. Sotalol is reasonable therapy to reduce symptoms
resulting from VT for patients with LV dysfunction
due to prior MI unresponsive to beta-blocking
agents. (Level of Evidence: C)
. Adjunctive therapies to the ICD, including catheter
ablation or surgical resection, and pharmacological
therapy with agents such as amiodarone or sotalol
are reasonable to improve symptoms due to frequent
episodes of sustained VT or VF in patients with LV
dysfunction due to prior MI. (Level of Evidence: C)
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toms due to recurrent hemodynamically stable VT for
patients with LV dysfunction due to prior MI who
cannot or refuse to have an ICD implanted. (Level of
Evidence: C)
. ICD implantation is reasonable for treatment of
recurrent sustained VT in patients post-MI with
normal or near normal ventricular function who are
receiving chronic optimal medical therapy, and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C)
lass IIb
. Curative catheter ablation or amiodarone may be
considered in lieu of ICD therapy to improve symp-
toms in patients with LV dysfunction due to prior MI
and recurrent hemodynamically stable VT whose EF
is greater than 40%. (Level of Evidence: B)
. Amiodarone may be reasonable therapy for patients
with LV dysfunction due to prior MI with an ICD
indication, as defined above, in patients who cannot
or refuse to have an ICD implanted. (Level of Evi-
dence: C)
lass III
. Prophylactic antiarrhythmic drug therapy is not
indicated to reduce mortality in patients with asymp-
tomatic nonsustained ventricular arrhythmias.
(Level of Evidence: B)
. Class IC antiarrhythmic drugs in patients with a
past history of MI should not be used. (Level of
Evidence: A)
Patients with chronic CHD manifest 3 general types of
entricular tachyarrhythmias: NSVT (defined as 3 or more
epetitive ventricular beats in a row lasting up to 30 s in
uration at a rate greater than 100 beats per minute),
ustained VT, and cardiac arrest resulting from VT or VF.
he cardiac mortality of patients with all types of ventricular
achyarrhythmias is high. The high mortality results from
onsudden, as well as sudden, cardiac death. These arrhyth-
ias may result from myocardial ischemia, or effects of HF,
n addition to primary electrical abnormalities.
Most NSVT in patients with chronic CHD is brief and
oes not cause symptoms. There is no evidence that
uppression of asymptomatic NSVT prolongs life. The
reatment of sustained VT in patients with chronic CHD
hould be tempered by the clinical manifestations produced
y the tachycardia, as well as the frequency of episodes.
atients experiencing cardiac arrest due to VF that does not
ccur within the first 24 to 48 h of acute MI may be at risk
or recurrent cardiac arrest.
All patients with CHD are at risk for SCD, and most
CD occurs in patients without severe LV dysfunction.
CD therapy is indicated to reduce the risk of SCD in 2atient groups: patients whose LVEF is less than or equal to
0% as a result of prior MI and who have spontaneous
SVT and sustained monomorphic VT inducible by EP
esting (50) and patients whose LVEF is less than 30% as a
esult of an MI that occurred greater than or equal to 40 d
arlier when HF (NYHA functional class II or III symp-
oms) is present (51). The use of antiarrhythmic agents may
redispose the patient to proarrhythmic complications that
ight pose significant threats to life. Increasingly, the ICD
s being used effectively to treat these arrhythmias, which in
hemselves may not be life-threatening, in order to avoid the
elative ineffectiveness and adverse complications of phar-
aceutical therapy.
. Valvular Heart Disease
ecommendations
lass I
Patients with valvular heart disease and ventricular
arrhythmias should be evaluated and treated follow-
ing current recommendations for each disorder.
(Level of Evidence: C)
lass IIb
The effectiveness of mitral valve repair or replace-
ment to reduce the risk of SCD in patients with
mitral valve prolapse, severe mitral regurgitation and
serious ventricular arrhythmias is not well estab-
lished. (Level of Evidence: C)
To date, there are insufficient data demonstrating
eduction in ventricular arrhythmias as a result of valve
epair or replacement in most patients with valvular
isease. For these reasons, patients with valvular heart
isease and ventricular arrhythmias should be evaluated
nd treated following current recommendations for each
isorder (104).
. Congenital Heart Disease
ecommendations
lass I
. ICD implantation is indicated in patients with
congenital heart disease who are survivors of
cardiac arrest after evaluation to define the cause
of the event and exclude any reversible causes.
ICD implantation is indicated in patients who are
receiving chronic optimal medical therapy and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: B)
. Patients with congenital heart disease and sponta-
neous sustained VT should undergo invasive hemo-
dynamic and EP evaluation. Recommended therapy
includes catheter ablation or surgical resection to
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tation is recommended. (Level of Evidence: C)
lass IIa
Invasive hemodynamic and EP evaluation is reason-
able in patients with congenital heart disease and
unexplained syncope and impaired ventricular func-
tion. In the absence of a defined and reversible cause,
ICD implantation is reasonable in patients who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: B)
lass IIb
EP testing may be considered for patients with
congenital heart disease and ventricular couplets or
NSVT to determine the risk of a sustained ventricu-
lar arrhythmia. (Level of Evidence: C)
lass III
Prophylactic antiarrhythmic therapy is not indicated
for asymptomatic patients with congenital heart dis-
ease and isolated PVCs. (Level of Evidence: C)
Congenital heart disease represents a diverse spectrum of
natomic and physiological defects with significant differ-
nces in respect to natural history, pre- and postoperative
hysiology as well as the risk of arrhythmias, appropriate
herapies and risk of late SCD.
During infancy and childhood, greater than 75% of
eaths in patients with congenital heart disease are in-
ospital events, most occurring during the perioperative
eriod (105). The remaining deaths occur as out-of-hospital
r emergency department events, often in patients with
ther congenital anomalies or sepsis.
Beyond 20 y of age, there is a progressive increase in the
ncidence of sudden and total cardiac mortality in postop-
rative congenital heart disease patients (106).
Five congenital heart defects have been associated with
he greatest risks of late SCD: tetralogy of Fallot, d- and
-transposition of the great arteries, aortic stenosis, and
unctional single ventricle (106–108). The largest number
f late SCD studies in postoperative patients with congen-
tal heart disease have been for tetralogy of Fallot.
In general, postoperative patients with unexplained syn-
ope should undergo both hemodynamic and EP evalua-
ion. A positive response to EP testing, independent of the
linical indication, may identify patients with a high risk of
ate SCD (109). In the absence of ventricular dysfunction or
ymptoms, isolated ventricular ectopy has minimal prognos-
ic significance, and the risks of antiarrhythmic drug treat-
ent can exceed any potential benefit (110).
The most common congenital coronary artery anomaly
ausing SCD in the young is anomalous origin of the left
oronary artery from the right sinus of Valsalva. The sroposed mechanism of SCD is that either acute angulation
f the coronary ostium or compression of the left coronary
rtery as it traverses the region between the aortic wall and
V outflow tract results in acute myocardial ischemia and
he development of VT or VF. Definitive diagnosis by
oronary angiography is an indication for surgical revascu-
arization.
Although disorders in this category are important causes
f life-threatening ventricular arrhythmias, the occurrence
f VT/SCD is relatively rare and, hence, in most cases, there
re few trial data as to how the arrhythmias should best be
anaged. Data relating to the prevention of life-threatening
entricular arrhythmias are even sparser.
Acute emergencies, as a consequence of any underlying
ilment in this section, should be managed conventionally.
. Metabolic and Inflammatory Conditions
. Myocarditis, Rheumatic Disease, and Endocarditis
ecommendations
lass I
. Temporary pacemaker insertion is indicated in pa-
tients with symptomatic bradycardia and/or heart
block during the acute phase of myocarditis. (Level of
Evidence: C)
. Acute aortic regurgitation associated with VT
should be treated surgically unless otherwise contra-
indicated. (Level of Evidence: C)
. Acute endocarditis complicated by aortic or annular
abscess and AV block should be treated surgically
unless otherwise contraindicated. (Level of Evidence:
C)
lass IIa
. ICD implantation can be beneficial in patients with
life-threatening ventricular arrhythmias who are not
in the acute phase of myocarditis, as indicated in the
ACC/AHA/NASPE 2002 Guideline Update for Im-
plantation of Cardiac Pacemakers and Antiarrhyth-
mia Devices (1) who are receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
. Antiarrhythmic therapy can be useful in patients
with symptomatic NSVT or sustained VT during the
acute phase of myocarditis. (Level of Evidence: C)
lass III
ICD implantation is not indicated during the acute
phase of myocarditis. (Level of Evidence: C)
Myocarditis is an inflammatory process affecting the
ardiac myocardium and is most often related to infection.
Cardiac arrhythmias associated with acute myocarditis
an range from conduction abnormalities to difficult to
uppress life-threatening ventricular arrhythmias. Death can
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111–118). Patients with arrhythmias or syncope may re-
uire antiarrhythmic drugs and/or device therapy (119).
emporary pacemaker insertion is indicated in patients with
cute myocarditis who present with symptomatic heart
lock as it would be in other causes of acute symptomatic
eart block.
Lyme carditis patients can develop varying degrees of AV
onduction abnormalities. Persistent heart block is rare, but
n such cases permanent pacing may be needed (120,121).
Chagas’ disease is caused by the protozoan Trypano-
oma cruzi and transmitted by an insect vector and is
ommon in Central and South America. Acute myocar-
itis is rare, but over one third develop late myocardial
amage with progressive HF and poor survival. Conduc-
ion defects with progression to complete heart block are
ommon. Life-threatening ventricular arrhythmias are
ommon. Amiodarone appears to be effective in treating
entricular tachyarrhythmias, and death occurs as a result
f either refractory HF or arrhythmias (122). Device
herapy including the ICD is frequently used in the late
hase (123).
Acute rheumatic fever, complete heart block, and ven-
ricular arrhythmias are rare (124–126). The development
f cardiac rhythm disturbances portends poorly in infective
ndocarditis (127).
. Infiltrative Cardiomyopathies
ecommendations
lass I
In addition to managing the underlying infiltrative
cardiomyopathy, life-threatening arrhythmias should
be treated in the same manner that such arrhythmias
are treated in patients with other cardiomyopathies,
including the use of ICD and pacemakers in patients
who are receiving chronic optimal medical therapy
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: C)
The association between the infiltrative cardiomyopathies
nd VT/SCD is well documented. In all cases, where
ppropriate, treatment of the underlying condition must
ccompany management of cardiac manifestations.
. Endocrine Disorders and Diabetes
ecommendations
lass I
. The management of ventricular arrhythmias sec-
ondary to endocrine disorders should address the
electrolyte (potassium, magnesium, and calcium)
imbalance and the treatment of the underlying
endocrinopathy. (Level of Evidence: C). Persistent life-threatening ventricular arrhythmias
that develop in patients with endocrine disorders
should be treated in the same manner that such
arrhythmias are treated in patients with other dis-
eases, including use of ICD and pacemaker implan-
tation as required in those who are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
. Patients with diabetes with ventricular arrhythmias
should generally be treated in the same manner as
patients without diabetes. (Level of Evidence: A)
Endocrine disorders can induce VT/SCD by excess or
nsufficient hormone activity on myocardial receptors
e.g., pheochromocytoma, hypothyroidism). The endo-
rinopathy can also cause myocardial changes (e.g., acro-
egaly) or electrolyte disturbances produced by hormone
xcess (e.g., hyperkalemia in Addison’s disease and hy-
okalemia in Conn’s syndrome) and certain endocrine
isorders can accelerate the progression of conditions
uch as underlying structural heart disease secondary to
yslipidemia or hypertension, increasing the risk of
erious arrhythmias.
. End-Stage Renal Failure
ecommendations
lass I
. The acute management of ventricular arrhythmias in
end-stage renal failure should immediately address
hemodynamic status and electrolyte (potassium,
magnesium, and calcium) imbalance. (Level of Evi-
dence: C)
. Life-threatening ventricular arrhythmias, especially
in patients awaiting renal transplantation, should be
treated conventionally, including the use of ICD
and pacemaker implantation as required, in patients
who are receiving chronic optimal medical therapy,
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: C)
Cardiovascular causes account for at least 40% of deaths
n patients with end-stage renal failure and 20% of these are
udden.
. Obesity, Dieting, and Anorexia
ecommendations
lass I
Life-threatening ventricular arrhythmias in patients
with obesity, anorexia, or when dieting should be
treated in the same manner that such arrhythmias are
treated in patients with other diseases, including
ICD and pacemaker implantation as required. Pa-
tients receiving ICD implantation should be receiv-
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sonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C)
lass IIa
Programmed weight reduction in obesity and care-
fully controlled re-feeding in anorexia can effectively
reduce the risk of ventricular arrhythmias and SCD.
(Level of Evidence: C)
lass III
Prolonged, unbalanced, very low calorie, semistarva-
tion diets are not recommended; they may be harmful
and provoke life-threatening ventricular arrhythmias.
(Level of Evidence: C)
Extreme disorders of eating, and overzealous methods of
ectifying them quickly, are all associated with SCD. In
verweight individuals, this risk is particularly evident in the
everely obese with a 40 to 60 times higher incidence
ompared to that in the age-matched general population
128,129).
Obstructive sleep apnea may play a role in the genesis of
rrhythmias and HF in obese individuals (130).
Reported mortality rates in anorexia nervosa fluctuate
rom 5% to 20%, but the actual rate is likely to be around 6%
131). Up to a third of these deaths, including those
ccurring during re-feeding, are said to be due to cardiac
auses but no precise data exist on SCD.
. Pericardial Diseases
ecommendations
lass I
Ventricular arrhythmias that develop in patients with
pericardial disease should be treated in the same
manner that such arrhythmias are treated in patients
with other diseases, including ICD and pacemaker
implantation as required. Patients receiving ICD
implantation should be receiving chronic optimal
medical therapy and have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: C)
. Pulmonary Arterial Hypertension
ecommendations
lass III
Prophylactic antiarrhythmic therapy generally is not
indicated for primary prevention of SCD in patients
with pulmonary arterial hypertension or other pul-
monary conditions. (Level of Evidence: C)
SCD is responsible for 30% to 40% of mortality in
atients with pulmonary arterial hypertension.. Transient Arrhythmias of Reversible Cause
ecommendations
lass I
. Myocardial revascularization should be performed,
when appropriate, to reduce the risk of SCD in
patients experiencing cardiac arrest due to VF or
polymorphic VT in the setting of acute ischemia or
MI. (Level of Evidence: C)
. Unless electrolyte abnormalities are proved to be the
cause, survivors of cardiac arrest due to VF or
polymorphic VT in whom electrolyte abnormalities
are discovered in general should be evaluated and
treated in a similar manner to that of cardiac arrest
without electrolyte abnormalities. (Level of Evidence: C)
. Patients who experience sustained monomorphic VT
in the presence of antiarrhythmic drugs or electrolyte
abnormalities should be evaluated and treated in a
manner similar to that of patients with VT without
electrolyte abnormalities or antiarrhythmic drugs
present. Antiarrhythmic drugs or electrolyte abnor-
malities should not be assumed to be the sole cause
of sustained monomorphic VT. (Level of Evidence: B)
. Patients who experience polymorphic VT in associ-
ation with prolonged QT interval due to antiar-
rhythmic medications or other drugs should be
advised to avoid exposure to all agents associated
with QT prolongation. A list of such drugs can be
found on the Web sites www.qtdrugs.org and www.
torsades.org. (Level of Evidence: B)
The mortality of cardiac arrest survivors is high, even
hen the cause of the initial arrest appears to be a transient
r correctable abnormality, and much of the mortality
ppears due to recurrent cardiac arrest (132, 133).
Observational studies suggest that
Sustained monomorphic VT in patients with prior MI is
unlikely to be affected by revascularization (134).
Myocardial revascularization is sufficient therapy only in
patients surviving VF in association with myocardial
ischemia when ventricular function is normal and there is
no history of MI (135).
V. VENTRICULAR ARRHYTHMIAS
SSOCIATED WITH CARDIOMYOPATHIES
. Dilated Cardiomyopathy (Nonischemic)
ecommendations
lass I
. EP testing is useful to diagnose bundle-branch
reentrant tachycardia and to guide ablation in
patients with nonischemic DCM. (Level of Evi-
dence: C)
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patients with nonischemic DCM with sustained pal-
pitations, wide-QRS-complex tachycardia, presyn-
cope, or syncope. (Level of Evidence: C)
. An ICD should be implanted in patients with non-
ischemic DCM and significant LV dysfunction who
have sustained VT or VF, who are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic DCM who have an LVEF
less than or equal to 30% to 35%, who are NYHA
functional class II or III, who are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: B) (See Section
IA.)
lass IIa
. ICD implantation can be beneficial for patients with
unexplained syncope, significant LV dysfunction,
and nonischemic DCM who are receiving chronic
optimal medical therapy and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
. ICD implantation can be effective for termination of
sustained VT in patients with normal or near normal
ventricular function and nonischemic DCM who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C) (See Section IA.)
lass IIb
. Amiodarone may be considered for sustained VT or
VF in patients with nonischemic DCM. (Level of
Evidence: C)
. Placement of an ICD might be considered in pa-
tients who have nonischemic DCM, who have
LVEF of less than or equal to 30% to 35%, who are
NYHA functional class I receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
Considerations taken by the Writing Committee in
ormulating recommendations for this section are discussed
n detail in the Introduction.
isk Stratification
The 5-y mortality for DCM has been recently esti-
ated at 20% with SCD accounting for approximately
0% (8% to 51%) of deaths (136,137). Ventricular
rrhythmias, both symptomatic and asymptomatic, are
ommon, but syncope and SCD are infrequent initialanifestations of the disease (138,139). The incidence of
CD is highest in patients with indicators of more
dvanced cardiac disease who are also at highest risk of
ll-cause mortality. Although VT and/or VF is consid-
red the most common mechanism of SCD, bradycardia,
ulmonary embolus, electromechanical dissociation, and
ther causes account for up to 50% of SCD in patients
ith advanced HF (140 –142).
In controlled trials, amiodarone reduced the incidence of
CD in a population of patients with predominately non-
schemic DCM (143) but not in a study of HF patients
here the majority had CHD (144). The ICD has been
hown to be superior to amiodarone for secondary preven-
ion of VT and VF in studies where the majority of patients
ad CHD (49,145,146). The subgroup with nonischemic
CM in these studies benefited from the ICD more than
hose with CHD (147).
The Defibrillators in Nonischemic Cardiomyopathy
reatment Evaluation (DEFINTE) trial (148–150) ran-
omized 458 patients with nonischemic DCM, EF less
han 35%, and frequent PVCs or NSVT to receive best
edical therapy with or without ICD. There was a trend
oward reduction of mortality with ICD therapy, but this
as not significant.
enetic Analysis
The clinical applicability of genetic analysis to DCM is
till limited as knowledge in this area does not allow
enotyping most individuals clinically affected by the
isease. Patients with DCM and AV block and patients
ith DCM and skeletal muscle diseases have higher
robability of being successfully genotyped. When a
athogenetic mutation is identified, it becomes possible
o establish a presymptomatic diagnosis of the disease
mong family members and provide them with genetic
ounseling to monitor progression of the disease and to
ssess the risk of transmitting the disease to offspring.
ased on current knowledge, genetic analysis does not
ontribute to risk stratification in DCM.
. Hypertrophic Cardiomyopathy
ecommendations
lass I
ICD therapy should be used for treatment in
patients with hypertrophic cardiomyopathy (HCM)
who have sustained VT and/or VF and who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of
Evidence: B)
lass IIa
. ICD implantation can be effective for primary pro-
phylaxis against SCD in patients with HCM who
have one or more major risk factor (see Table 7) for
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therapy and in patients who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
. Amiodarone therapy can be effective for treatment in
patients with HCM with a history of sustained VT
and/or VF when ICD is not feasible. (Level of
Evidence: C)
lass IIb
. EP testing may be considered for risk assessment for
SCD in patients with HCM. (Level of Evidence: C)
. Amiodarone may be considered for primary prophylaxis
against SCD in patients with HCM who have one or
more major risk factor for SCD (see Table 7), if ICD
implantation is not feasible. (Level of Evidence: C)
isk Stratification
Most individuals with HCM are asymptomatic and the first
anifestation may be SCD (151–157). SCD is usually related
o ventricular arrhythmia with a variable contribution of
riggers such as ischemia, outflow obstruction, or atrial fibril-
ation (153–156,158). This relatively low incidence creates a
hallenge for risk stratification since the false-positive results
or any stratifier may overwhelm the true-positive results (159).
n one study, 23 of 480 patients died suddenly over a mean
ollow-up of 6.5 y (160). The risk of SCD was directly related
o LV wall thickness with essentially no mortality over 20 y
ith wall thickness less than 20 mm and almost 40% for wall
hickness greater than or equal to 30 mm.
A consensus document on HCM from the ACC and ESC
ategorized the known risk factors for SCD as “major” and
possible in individual patients” (161) as follows in Table 7.
anagement
The mainstay of pharmacological management for the
ymptomatic patient has been beta blockers or verapamil,
hich probably exert their effect by reducing heart rate and
ecreasing contractility (153,162). Amiodarone is widely
able 7. Risk Factors for Sudden Cardiac Death in
ypertrophic Cardiomyopathy
Major Risk Factors
Possible in Individual
Patients
ardiac arrest (VF) AF
pontaneous sustained VT Myocardial ischemia
amily history of premature sudden death LV outflow obstruction
nexplained syncope High-risk mutation
V thickness greater than or equal to 30 mm Intense (competitive)
physical exertionbnormal exercise BP
onsustained spontaneous VT
odified with permission from Maron BJ, McKenna WJ, Danielson GK, et al.
merican College of Cardiology/European Society of Cardiology clinical expert
onsensus document on hypertrophic cardiomyopathy. A report of the American
ollege of Cardiology Foundation Task Force on Clinical Expert Consensus
ocuments and the European Society of Cardiology Committee for Practice
uidelines. J Am Coll Cardiol 2003;42:1687–713.
AF  atrial fibrillation; BP  blood pressure; LV  left ventricular; VF 
entricular fibrillation; VT  ventricular tachycardia.sed and considered the most effective antiarrhythmic bgent, although large controlled comparative trials are not
vailable (163,164).
Although there are no randomized studies available, the
CD has been used in patients with cardiac arrest, sustained
T or VF with a high percentage of patients receiving
ppropriate discharge during follow-up at a rate of 11% per
ear (165).
enetic Analysis
Genetic analysis is useful in families with HCM because
henever a pathogenetic mutation is identified, it becomes
ossible to establish a presymptomatic diagnosis of the disease
mong family members and to provide them with genetic
ounseling to assess the risk of disease development and
ransmission of the disease to offspring. Genetic analysis may
ontribute to risk stratification in selected circumstances.
. Arrhythmogenic Right Ventricular Cardiomyopathy
ecommendations
lass I
ICD implantation is recommended for prevention of
SCD inpatientswith arrhythmogenicRVcardiomyopathy
with documented sustained VT or VF who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: B)
lass IIa
. ICD implantation can be effective for prevention of
SCD in patients with arrhythmogenic RV cardiomy-
opathy with extensive disease, including those with
LV involvement, one or more affected family mem-
ber with SCD, or undiagnosed syncope when VT or
VF has not been excluded as the cause of syncope,
who are receiving chronic optimal medical therapy,
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: C)
. Amiodarone or sotalol can be effective for treatment
of sustained VT or VF in patients with arrhythmo-
genic RV cardiomyopathy when ICD implantation
is not feasible. (Level of Evidence: C)
. Ablation can be useful as adjunctive therapy in man-
agement of patients with arrhythmogenic RV cardio-
myopathy with recurrent VT, despite optimal anti-
arrhythmic drug therapy. (Level of Evidence: C)
lass IIb
EP testing might be useful for risk assessment of
SCD in patients with arrhythmogenic RV cardiomy-
opathy. (Level of Evidence: C)
isk Stratification
Patients with arrhythmogenic RV cardiomyopathy (“dys-
lasia”) have ventricular arrhythmias with left bundle-
ranch block morphology that span the spectrum of simple
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ately, SCD is frequently the first manifestation of the
isease (167–169).
anagement
The ICD has been used in patients with unexplained
yncope, sustained VT, or VF with a high incidence of
ppropriate shocks (170). Although there are no specific
arge randomized trials in arrhythmogenic RV cardiomyop-
thy to support this, the situation is sufficiently “similar” to
hose disease states such as previous MI where these
ndications are well established (49,171–173).
enetic Analysis
Genetic analysis is useful in families with RV cardiomy-
pathy because whenever a pathogenetic mutation is iden-
ified, it becomes possible to establish a presymptomatic
iagnosis of the disease among family members and to
rovide them with genetic counseling to monitor the
evelopment of the disease and to assess the risk of
ransmitting the disease to offspring. Based on current
nowledge, genetic analysis does not contribute to risk
tratification of arrhythmogenic RV cardiomyopathy.
. Neuromuscular Disorders
ecommendations
lass I
Patients with neuromuscular disorders who have
ventricular arrhythmias should generally be treated in
the same manner as patients without neuromuscular
disorders. (Level of Evidence: A)
lass IIb
Permanent pacemaker insertion may be considered
for neuromuscular diseases such as myotonic muscu-
lar dystrophy, Kearns-Sayre syndrome, Erb’s dystro-
phy, and peroneal muscular atrophy with any degree
of AV block (including first-degree AV block) with or
without symptoms, because there may be unpredict-
able progression of AV conduction disease. (Level of
Evidence: B)
The inherited neuromuscular disorders may predispose to
trial arrhythmias, conduction defects, advanced AV block,
onomorphic VT, polymorphic VT, and SCD (174–183).
The clinical presentation, indicating the potential sub-
trate for SCD, is quite variable because SCD is a
ell-recognized complication of some of the neuromus-
ular diseases and progression of the conduction abnor-
alities may be unpredictable (184 –190). Once cardiac
nvolvement occurs, particularly with the muscular dys-
rophies, the clinician should maintain a low threshold
or investigating symptoms or ECG findings to deter-
ine the need for pacemaker insertion, invasive EPtudies, or ICD implantation.VI. HEART FAILURE
ecommendations
lass I
. ICD therapy is recommended for secondary preven-
tion of SCD in patients who survived VF or hemo-
dynamically unstable VT, or VT with syncope and
who have an LVEF less than or equal to 40%, who are
receiving chronic optimal medical therapy and who
have a reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who
are at least 40 d post-MI, have an LVEF less than or
equal to 30% to 40%, are NYHA functional class II or
III, are receiving chronic optimal medical therapy,
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: A) (See Section IA.)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic heart disease who have an
LVEF less than or equal to 30% to 35%, are NYHA
functional class II or III receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for more
than 1 y. (Level of Evidence: B) (See Section IA.)
. Amiodarone, sotalol and/or other beta blockers are
recommended pharmacological adjuncts to ICD
therapy to suppress symptomatic ventricular tachy-
arrhythmias (both sustained and nonsustained) in
otherwise optimally treated patients with HF. (Level
of Evidence: C)
. Amiodarone is indicated for the suppression of acute
hemodynamically compromising ventricular or su-
praventricular tachyarrhythmias when cardioversion
and/or correction of reversible causes have failed to
terminate the arrhythmia or prevent its early recur-
rence. (Level of Evidence: B)
lass IIa
. ICD therapy combined with biventricular pacing
can be effective for primary prevention to reduce
total mortality by a reduction in SCD, in patients
with NYHA functional class III or IV receiving
optimal medical therapy, in sinus rhythm with a
QRS complex of at least 120 ms and who have
reasonable expectation of survival with a good func-
tional status for more than 1 y. (Level of Evidence: B)
. ICD therapy is reasonable for primary prevention to
reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who
are at least 40 d post-MI, have an LVEF of less than
34
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I, are receiving chronic optimal medical therapy, and
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: B) (See Section IA.)
. ICD therapy is reasonable in patients who have
recurrent stable VT, a normal or near normal LVEF,
and optimally treated HF and who have a reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
. Biventricular pacing in the absence of ICD therapy
is reasonable for the prevention of SCD in patients
with NYHA functional class III or IV HF, an LVEF
less than or equal to 35% and a QRS complex equal
to or wider than 160 ms (or at least 120 ms in the
presence of other evidence of ventricular dyssyn-
chrony) who are receiving chronic optimal medical
therapy and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B)
lass IIb
. Amiodarone, sotalol, and/or beta blockers may be
considered as pharmacological alternatives to ICD
therapy to suppress symptomatic ventricular tachy-
arrhythmias (both sustained and nonsustained) in
optimally treated patients with HF for whom ICD
therapy is not feasible. (Level of Evidence: C)
. ICD therapy may be considered for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic heart disease who have an
LVEF of less than or equal to 30% to 35%, are NYHA
functional class I receiving chronic optimal medical
therapy, and who have a reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B) (See Section IA.)
Considerations taken by the Writing Committee in
ormulating recommendations for this section are discussed
n detail in the Introduction.
Ventricular arrhythmias and SCD are common in patients
ith symptomatic acute and chronic HF and LV systolic
ysfunction. The cause of HF likely influences the mechanisms
nd types of ventricular arrhythmias. The guidelines and
omments in this section refer to patients with symptomatic
F; not just abnormal LVEF (refer to the ACC/AHA 2005
uideline Update for the Diagnosis and Management of
hronic Heart Failure in the Adult for definitions [6]).
In the setting of acute HF, ventricular arrhythmias may
e especially poorly tolerated and early cardioversion should
e performed, rather than attempting pharmacological ter-
ination of arrhythmia.
There is no evidence that suppression of NSVT has a
avorable effect on prognosis in patients with HF (144).
hus, asymptomatic NSVT should not be treated by anti-rrhythmic medication. If NSVT causes symptoms thatequire therapy, amiodarone is probably the safest agent to
se for treatment.
SCD accounts for approximately 50% of deaths in pa-
ients with HF. However, there is little evidence that
mpiric antiarrhythmic therapy can reduce the risk of SCD.
The SCD-HeFT trial showed no survival benefit to
atients with HF (NYHA functional class II and III) and
VEF less than or equal to 35% treated with amiodarone
mpirically (8).
ICD therapy has not improved survival of patients with
F due to nonischemic DCM in 2 small trials (191,192).
owever, the SCD-HeFT trial demonstrated a 23% reduc-
ion in total mortality with ICD treatment in comparison to
lacebo (8). These results are consistent with results of
EFINTE and earlier trials of patients with CHD and LV
ysfunction, some of whom had symptomatic HF
47,50,51). ICD in combination with biventricular pacing
ay improve survival and improve symptoms of patients
ith advanced HF (NYHA functional class III and IV) over
hort-term follow-up (1 to 2 y).
The value of biventricular pacing without additional ICD
upport for the reduction of SCD remains controversial (193,194).
VII. GENETIC ARRHYTHMIA SYNDROMES
. General Concepts for Risk Stratification
QTS, Brugada syndrome, and catecholaminergic poly-
orphic ventricular tachycardia (Online Mendelian Inher-
tance in Man [OMIM] Nos. 192500, 152427, 603830,
00919, 176261, 603796, 601144, and 604772) (195) are
nherited arrhythmogenic diseases. They share genetically
etermined susceptibility to VT and SCD in the absence of
ecognizable structural abnormalities of the heart. These
yndromes are by definition rare diseases because they have
n estimated prevalence below 5 in 10 000 (196).
. Long QT Syndrome
ecommendations
lass I
. Lifestyle modification is recommended for patients
with an LQTS diagnosis (clinical and/or molecular).
(Level of Evidence: B)
. Beta blockers are recommended for patients with an
LQTS clinical diagnosis (i.e., in the presence of
prolonged QT interval). (Level of Evidence: B)
. Implantation of an ICD along with use of beta
blockers is recommended for LQTS patients with
previous cardiac arrest and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
lass IIa
. Beta blockers can be effective to reduce SCD in
patients with a molecular LQTS analysis and nor-
mal QT interval. (Level of Evidence: B)
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blockers can be effective to reduce SCD in LQTS
patients experiencing syncope and/or VT while
receiving beta blockers and who have reasonable
expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: B)
lass IIb
. Left cardiac sympathetic neural denervation may be
considered for LQTS patients with syncope, torsades
de pointes, or cardiac arrest while receiving beta
blockers. (Level of Evidence: B)
. Implantation of an ICD with use of beta blockers
may be considered for prophylaxis of SCD for pa-
tients in categories possibly associated with higher
risk of cardiac arrest such as LQT2 and LQT3 and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: B)
Even before the identification of the genetic subtypes,
T interval duration was identified as the strongest predic-
or of risk for cardiac events (syncope, SCD) in LQTS
197), and it remains so. A normal QT interval in an
ngenotyped family member portends a good prognosis
198). A QTc exceeding 500 ms (corresponding to the
pper QTc quartile among affected genotyped individuals)
dentifies patients with the highest risk of becoming symp-
omatic by age 40 y (199). Patients with the Jervell Lange-
ielsen and other homozygous syndromes and patients with
QTS associated with syndactyly (200,201) are at higher
isk.
Patients resuscitated from SCD have an especially omi-
ous prognosis with a relative risk of 12.9 of experiencing
nother cardiac arrest (202). Syncope in LQTS patients is
sually attributed to severe ventricular arrhythmias, al-
hough other causes can occur.
ifestyle Changes
It is recommended that all patients affected by LQTS
void competitive sports activity (203). For LQT1 pa-
ients, swimming should be specifically limited or per-
ormed under supervision. LQT2 patients should avoid
xposure to acoustic stimuli especially during sleep
avoidance of telephone and alarm clock on the night-
tand). All patients with LQTS should avoid drugs
nown to prolong the QT interval and those that deplete
otassium/magnesium.
enetic Analysis
Genetic analysis is very important for identifying all
utation carriers within an LQTS family: Once identified,
ilent carriers of LQTS genetic defects may be treated with
eta blockers for prophylaxis of life-threatening arrhyth-
ias. Furthermore, silent mutation carriers should receive
enetic counseling to learn about the risk of transmitting
QTS to offspring.In patients affected by LQTS, genetic analysis is useful
or risk stratification (199) and for making therapeutic
ecisions (204). Although genetic analysis is not yet widely
vailable, it is advisable to try to make it accessible to LQTS
atients.
ndersen Syndrome
Little is known about risk stratification and manage-
ent of patients with Andersen syndrome. Patients seem
o have ventricular arrhythmias but not a high incidence
f cardiac arrest: The benefit of prophylactic treatment
ith beta blockers has not been defined even if most
atients with prolonged QT are usually treated with these
gents on empiric grounds. The beneficial role of calcium
hannel blockers has also been proposed on the basis of
he arrhythmia-suppression observed in a single patient
205).
. Short QT Syndrome and Brugada Syndrome
ecommendations
lass I
An ICD is indicated for Brugada syndrome patients
with previous cardiac arrest receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
lass IIa
. An ICD is reasonable for Brugada syndrome pa-
tients with spontaneous ST-segment elevation in
V1, V2, or V3 who have had syncope with or without
mutations demonstrated in the SCN5A gene and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: C)
. Clinical monitoring for the development of a spon-
taneous ST-segment elevation pattern is reasonable
for the management of patients with ST-segment
elevation induced only with provocative pharmaco-
logical challenge with or without symptoms. (Level
of Evidence: C)
. An ICD is reasonable for Brugada syndrome pa-
tients with documented VT that has not resulted in
cardiac arrest and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
. Isoproterenol can be useful to treat an electrical storm
in the Brugada syndrome. (Level of Evidence: C)
lass IIb
. EP testing may be considered for risk stratification
in asymptomatic Brugada syndrome patients with
spontaneous ST elevation with or without a muta-
tion in the SCN5A gene. (Level of Evidence: C)
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electrical storm in patients with Brugada syndrome.
(Level of Evidence: C)
The Brugada syndrome is associated with a characteris-
ically abnormal ECG and a high risk of SCD in individuals
ith a structurally normal heart (206).
SCD is caused by rapid polymorphic VT or VF
requently occurring at rest or during sleep. Quinidine
nd isoproterenol may be useful in patients with arrhyth-
ia storm even in the presence of an ICD (207–209).
enetic Analysis—Brugada Syndrome
Genetic analysis may help identify silent carriers of
rugada syndromerelated mutations so that they can
emain under clinical monitoring to detect early manifesta-
ions of the syndrome. Furthermore, once identified, silent
utation carriers should receive genetic counseling and
iscuss the risk of transmitting the disease to offspring.
ased on current knowledge, genetic analysis does not
ontribute to risk stratification.
enetic Analysis—Short QT Syndrome
Genetic analysis may help identify silent carriers of short
T syndrome related mutations; however, the risk of
ardiac events in genetically affected individuals with a
ormal ECG is currently not known. The risk is also
nknown because of the limited number of patients with
hort QT syndrome identified to date. At present, genetic
nalysis does not contribute to risk stratification.
. Catecholaminergic Polymorphic
entricular Tachycardia
ecommendations
lass I
. Beta blockers are indicated for patients who are
clinically diagnosed with catecholaminergic poly-
morphic VT on the basis of the presence of sponta-
neous or documented stress-induced ventricular ar-
rhythmias. (Level of Evidence: C)
. Implantation of an ICD with use of beta blockers is
indicated for patients with catecholaminergic poly-
morphic VT who are survivors of cardiac arrest and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: C)
lass IIa
. Beta blockers can be effective in patients without
clinical manifestations when the diagnosis of cat-
echolaminergic polymorphic VT is established dur-
ing childhood based on genetic analysis. (Level of
Evidence: C)
. Implantation of an ICD with use of beta blockers
can be effective for affected patients with cat-
echolaminergic polymorphic VT with syncopeand/or documented sustained VT while receiving
beta blockers and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
lass IIb
Beta blockers may be considered for patients with
catecholaminergic polymorphic VT who were genet-
ically diagnosed in adulthood and never manifested
clinical symptoms of tachyarrhythmias. (Level of Ev-
idence: C)
Catecholaminergic polymorphic VT is characterized by
entricular tachyarrhythmias that develop during physical
ctivity or acute emotion in the presence of an unremarkable
esting ECG (210).
enetic Analysis
Genetic analysis may help identify silent carriers of
atecholaminergic VT related mutations; once identified,
ilent carriers may be treated with beta blockers to reduce
he risk of cardiac events and may receive appropriate
enetic counseling to assess the risk of transmitting the
isease to offspring. Based on current knowledge, genetic
nalysis does not contribute to further risk stratification.
VIII. ARRHYTHMIAS IN
TRUCTURALLY NORMAL HEARTS
. Idiopathic Ventricular Tachycardia
ecommendations
lass I
Catheter ablation is useful in patients with structur-
ally normal hearts with symptomatic, drug refractory
VT arising from the RV or LV or in those who are
drug intolerant or who do not desire long-term drug
therapy. (Level of Evidence: C)
lass IIa
. EP testing is reasonable for diagnostic evaluation in
patients with structurally normal hearts with palpi-
tations or suspected outflow tract VT. (Level of
Evidence: B)
. Drug therapy with beta blockers and/or calcium chan-
nel blockers (and/or IC agents in RV outflow tract
[RVOT] VT) can be useful in patients with structur-
ally normal hearts with symptomatic VT arising from
the right ventricle. (Level of Evidence: C)
. ICD implantation can be effective therapy for ter-
mination of sustained VT in patients with normal
or near normal ventricular function and no struc-
tural heart disease who are receiving chronic opti-
mal medical therapy and who have reasonable ex-
pectation of survival for more than 1 y. (Level of
Evidence: C)
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utflow Tract Ventricular Tachycardia
VT arising from the right ventricle is the most common
orm of VT in apparently healthy people and is associated
ith a good prognosis in those without overt structural heart
isease (73,76,93,97,211–221). This VT usually has a left
undle-branch, inferior axis morphology.
Clinical treatment of RVOT or LVOT VT often involves
eta and calcium-channel blockers. Type IC antiarrhythmic
rugs have been found useful in RVOT VT (97,214,222–
25). In patients who remain symptomatic or who fail drug
herapy, catheter ablation of the arrhythmia focus in the
VOT should be considered.
So-called idiopathic LV VT can arise from the LVOT or
rom the fascicles of the specialized conduction system. Left
ascicular VT typically is reentrant and may respond to beta
lockers or to calcium-channel blockers.
. Electrolyte Disturbances
ecommendations
lass I
Potassium (and magnesium) salts are useful in treating
ventricular arrhythmias secondary to hypokalemia (or hy-
pomagnesemia) resulting from diuretic use in patients
with structurally normal hearts. (Level of Evidence: B)
lass IIa
. It is reasonable to maintain serum potassium levels
above 4.0 mM/L in any patient with documented
life-threatening ventricular arrhythmias and a struc-
turally normal heart. (Level of Evidence: C)
. It is reasonable to maintain serum potassium levels
above 4.0 mM/L in patients with acute MI. (Level of
Evidence: B)
. Magnesium salts can be beneficial in the management
of VT secondary to digoxin toxicity in patients with
structurally normal hearts. (Level of Evidence: B)
A rapid rise in extracellular potassium, hypokalemia (less
han 3.5 mM), and hypomagnesemia are all associated with
entricular arrhythmias and SCD in patients with structur-
lly normal hearts (some of whom may have underlying
hannelopathies) and in an acute MI setting (226–240).
ypomagnesemia is classically associated with polymorphic
T or torsades de pointes, which together with ventricular
rrhythmias in an acute MI setting, may respond to intra-
enous magnesium (241–244). Hypokalemia with or with-
ut hypomagnesemia may be responsible for ventricular
rrhythmias in subjects with hypertension and congestive
ardiac failure (precipitated by the use of thiazide and loop
iuretics) (227,228,245), acute starvation (246), acute alco-
ol toxicity/withdrawal, and those with ventricular arrhyth-
ias associated with digoxin and other Vaughan Williams
lass III antiarrhythmic drugs (238,247,248). Significant
ypocalcemia can prolong the QT interval. e. Physical and Toxic Agents
ecommendations
lass I
. Complete abstinence from alcohol is recommended
in cases where there is a suspected correlation be-
tween alcohol intake and ventricular arrhythmias.
(Level of Evidence: C)
. Persistent life-threatening ventricular arrhythmias
despite abstinence from alcohol should be treated in
the same manner that such arrhythmias are treated in
patients with other diseases, including an ICD, as
required, in patients receiving chronic optimal med-
ical therapy and who have reasonable expectation of
survival for more than 1 y. (Level of Evidence: C)
The relationship between alcohol ingestion and VT/SCD
s indisputable; what is controversial however, is its exact
ature (249). A number of studies claim a J-shaped rela-
ionship with risk lowest in individuals with low alcohol
ntake (i.e., 2 to 6 drinks per week) compared to those who
arely or never consume alcohol (250) and those with a high
lcohol intake (i.e., greater than 3 to 5 drinks per day)
251,252) and binge drinking habits, the so called “holiday
eart syndrome” (253–256).
. Smoking
ecommendations
lass I
Smoking should be strongly discouraged in all
patients with suspected or documented ventricular
arrhythmias and/or aborted SCD. (Level of Evi-
dence: B)
Cigarette smoking is an independent risk factor for SCD
rrespective of underlying CHD (257–261). Cessation of
moking significantly reduces risk of SCD.
. Lipids
ecommendations
lass I
Statin therapy is beneficial in patients with CHD to
reduce the risk of vascular events, possibly ventricular
arrhythmias, and SCD. (Level of Evidence: A)
lass IIb
n-3 polyunsaturated fatty acid supplementation may
be considered for patients with ventricular arrhyth-
mias and underlying CHD. (Level of Evidence: B)
The association of high total, VLDL, or LDL cholesterol
evels, a low HDL cholesterol level together with high
riglyceride and apolipoprotein B levels with increased risk
f VT/SCD is almost entirely due to concurrent CHD. The
ffect of lipid lowering on SCD in primary prevention has
n
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0% would be expected in parallel with the reduction in the
isk of CHD death (262,263).
Free fatty acid or nonesterified fatty acid levels are also an
ndependent risk factors for SCD but not fatal MI (264).
IX. VENTRICULAR ARRHYTHMIAS
ND SUDDEN CARDIAC DEATH
ELATED TO SPECIFIC POPULATIONS
. Athletes
ecommendations
lass I
. Preparticipation history and physical examination,
including family history of premature or SCD and
specific evidence of cardiovascular diseases such as
cardiomyopathies and ion channel abnormalities is
recommended in athletes. (Level of Evidence: C)
. Athletes presenting with rhythm disorders, structural
heart disease, or other signs or symptoms suspicious
for cardiovascular disorders, should be evaluated as
any other patient but with recognition of the poten-
tial uniqueness of their activity. (Level of Evidence: C)
. Athletes presenting with syncope should be carefully
evaluated to uncover underlying cardiovascular dis-
ease or rhythm disorder. (Level of Evidence: B)
. Athletes with serious symptoms should cease com-
petition while cardiovascular abnormalities are being
fully evaluated. (Level of Evidence: C)
lass IIb
Twelve-lead ECG and possibly echocardiography
may be considered as preparticipation screening for
heart disorders in athletes. (Level of Evidence: B)
It is generally accepted that preparticipation screening for
edical conditions should be a requirement for clearance to
articipate in competitive athletics, but there are no uni-
ormly accepted standards for screening.
The major causes of SCD in athletes are HCM (36%)
nd coronary artery anomalies (19%), arrhythmogenic RV
ardiomyopathy, and myocarditis.
Screening of athletes is a difficult task. The low incidence
f anomalies makes screening not very cost effective, al-
hough one study has suggested that ECG screening is more
ost effective than echocardiographic screening (265,266).
. Gender and Pregnancy
ecommendations
lass I
. Pregnant women developing hemodynamically unsta-
ble VT or VF should be electrically cardioverted or
defibrillated. (Level of Evidence: B) (See Section XIII.) S. In pregnant women with the LQTS who have had symp-
toms, it is beneficial to continue beta-blocker medications
throughout pregnancy and afterward, unless there are
definite contraindications. (Level of Evidence: C)
T Interval
Typically, women have longer QT intervals than do men,
nd this difference is more pronounced at slower heart rates.
he incidence of both congenital and acquired forms of
ong QT intervals and resultant torsades de pointes is higher
n women than in men (197,267). Palpitations are extremely
ommon during pregnancy and several studies have shown
n increase in the symptoms of supraventricular tachycardia
SVT) during pregnancy (268–270).
VT occurs in the absence of overt structural heart disease
nd may be related to elevated catecholamines (271). As such,
hese arrhythmias may be beta-blocker sensitive. In women
resenting with new onset VT during the last 6 wk of
regnancy or in the early postpartum period, the possibility of
ostpartum cardiomyopathy should be ruled out (272).
Potentially life-threatening ventricular tachyarrhythmias
hould be terminated by electrical cardioversion. Beta 1se-
ective beta blockers alone, amiodarone alone (noting cau-
ions about birth defects above) or in combination may be
sed, and ICD may be needed as its presence does not
ontraindicate future pregnancies.
. Elderly Patients
ecommendations
lass I
. Elderly patients with ventricular arrhythmias should
generally be treated in the same manner as younger
individuals. (Level of Evidence: A)
. The dosing and titration schedule of antiarrhythmic
drugs prescribed to elderly patients should be ad-
justed to the altered pharmacokinetics of such pa-
tients. (Level of Evidence: C)
lass III
Elderly patients with projected life expectancy less
than 1 y due to major comorbidities should not
receive ICD therapy. (Level of Evidence: C)
Ventricular arrhythmias are common in elderly popula-
ions and the incidence increases in the presence of struc-
ural heart disease (273–276).
Complex ventricular arrhythmias often presage new ma-
or coronary events and SCD in patients with CHD and
ther types of structural heart disease (277,278). The
ncidence of SCD increases with advancing age (279,280).
The management of ventricular arrhythmias and the pre-
ention of SCD in elderly patients do not differ appreciably
rom that recommended for the general population. Despite
he demonstrated efficacy in reducing all-cause mortality and
CD, beta blockers are underused in the elderly.
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he efficacy of ICDs in reducing SCD in patients with
HD at high risk for SCD (primary prevention) and in
atients resuscitated from SCD (secondary prevention)
hen compared with antiarrhythmic drug therapy across all
ge groups (47,49–51,145,146).
All previously referenced studies included substantial
umbers of patients over the age of 65 y. Subgroup analysis
n Antiarrhythmics Versus Implantable Defibrillators
AVID) and MADIT II trials demonstrated equivalent
enefits from ICD implantation in older and younger
atients (49,51).
Several observational studies have shown that the invasive
pproach in managing patients with life-threatening ventricu-
ar arrhythmias is equally beneficial in the elderly and in
ounger patients (281–283). Very elderly patients with multi-
le comorbidities and limited life expectancy may not be
ppropriate candidates for ICD therapy even if they meet
tandard criteria.
. Pediatric Patients
ecommendations
lass I
. An ICD should be implanted in pediatric survivors
of a cardiac arrest, when a thorough search for a
correctable cause is negative and the patients are
receiving optimal medical therapy and have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C)
. Hemodynamic and EP evaluation should be per-
formed in the young patient with symptomatic,
sustained VT. (Level of Evidence: C)
. ICD therapy in conjunction with pharmacological
therapy is indicated for high-risk pediatric patients
with a genetic basis (ion channel defects or cardio-
myopathy) for either SCD or sustained ventricular
arrhythmias. The decision to implant an ICD in a
child must consider the risk of SCD associated with
the disease, potential equivalent benefit of medical
therapy as well as risk of device malfunction, infec-
tion or lead failure and that there is reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
lass IIa
. ICD therapy is reasonable for pediatric patients with
spontaneous sustained ventricular arrhythmias asso-
ciated with impaired (LVEF of 35% or less) ventric-
ular function receiving chronic optimal medical
therapy and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B)
. Ablation can be useful in pediatric patients with
symptomatic outflow tract or septal VT that isdrug resistant, when the patient is drug intolerant
or wishes not to take drugs. (Level of Evidence: C)
lass III
. Pharmacological treatment of isolated PVCs in pe-
diatric patients is not recommended. (Level of Evi-
dence: C)
. Digoxin or verapamil should not be used for treat-
ment of sustained tachycardia in infants when VT has
not been excluded as a potential diagnosis. (Level of
Evidence: C)
. Ablation is not indicated in young patients with
asymptomatic NSVT and normal ventricular func-
tion. (Level of Evidence: C)
The incidence of SCD due to cardiovascular disease is
ignificantly less in pediatric than adult patients.
Several groups of young patients have been identified who
re at an increased risk of SCD compared to the general
opulation. These include patients with congenital heart
isease, coronary artery anomalies, cardiomyopathies, and
rimary arrhythmic diagnoses such as the LQTSs (284).
ustained ventricular arrhythmias may also occur in infants,
ost commonly an accelerated idioventricular rhythm. VF
nd SCD have been reported in these infants, most often
ollowing the administration of intravenous digoxin or
erapamil for a presumptive diagnosis of SVT (285,286).
eyond the first year of life, most children with complex
ctopy or hemodynamically tolerated VT appear to have a
ood prognosis (287,288).
The role and benefit of ICD implantation for prevention
f SCD in young children with advanced ventricular dys-
unction have not been defined. In older children and
dolescents, prophylactic ICD implantation may be consid-
red, based on data derived from adult randomized clinical
rials of similar patients (8,42).
. Patients With Implantable Cardioverter-Defibrillators
ecommendations
lass I
. Patients with implanted ICDs should receive regular
follow-up and analysis of the device status. (Level of
Evidence: C)
. Implanted ICDs should be programmed to obtain
optimal sensitivity and specificity. (Level of Evi-
dence: C)
. Measures should be undertaken tominimize the risk of
inappropriate ICD therapies. (Level of Evidence: C)
. Patients with implanted ICDs who present with
incessant VT should be hospitalized for manage-
ment. (Level of Evidence: C)
C1
2
i
f
g
l
f
i
a
T
a
F
R
C
C
1
2
C
C
t
t
d
p
F
g
t
(
G
R
C
C
1
2
C
m
p
p
i
p
n
l
.
t
m
p
t
t
g
1094 Zipes et al. JACC Vol. 48, No. 5, 2006
ACC/AHA/ESC Practice Guidelines—Executive Summary September 5, 2006:1064–1108lass IIa
. Catheter ablation can be useful for patients with
implanted ICDs who experience incessant or fre-
quently recurring VT. (Level of Evidence: B)
. In patients experiencing inappropriate ICD therapy,
EP evaluation can be useful for diagnostic and
therapeutic purposes. (Level of Evidence: C)
The placement of an ICD does not, in itself, decrease the
ncidence of arrhythmias, although the patient is protected
rom the consequences of the arrhythmias.
SVT may trigger ICD action due to fulfilling pro-
rammed ventricular or SVT detection criteria. Atrial fibril-
ation is the most frequent culprit arrhythmia.
Dual-chamber ICDs provide improved atrial diagnostic
eatures with recording of local atrial electrograms, regular-
ty of atrial signals, and cycle lengths.
High drug concentrations due to overdose or drug inter-
ctions generally increase risk of drug-induced arrhythmias.
able 8 lists examples of drug interactions that may cause
rrhythmias.
. Digitalis Toxicity
ecommendations
lass I
An antidigitalis antibody is recommended for pa-
tients who present with sustained ventricular ar-
rhythmias, advanced AV block, and/or asystole that
are considered due to digitalis toxicity. (Level of
Evidence: A)
lass IIa
. Patients taking digitalis who present with mild
cardiac toxicity (e.g., isolated ectopic beats only), can
be managed effectively with recognition, continuous
monitoring of cardiac rhythm, withdrawal of digi-
talis, restoration of normal electrolyte levels (includ-
ing serum potassium greater than 4 mM/L) and
oxygenation. (Level of Evidence: C)
. Magnesium or pacing is reasonable for patients who
take digitalis and present with severe toxicity (sus-
tained ventricular arrhythmias, advanced AV block,
and/or asystole). (Level of Evidence: C)
lass IIb
Dialysis for the management of hyperkalemia may be
considered for patients who take digitalis and present
with severe toxicity (sustained ventricular arrhyth-
mias, advanced AV block, and/or asystole). (Level of
Evidence: C)
lass III
Management by lidocaine or phenytoin is not recom-
mended for patients taking digitalis and who present
with severe toxicity (sustained ventricular arrhyth- mmias, advanced AV block, and/or asystole). (Level of
Evidence: C)
Certain arrhythmias are typical: enhanced atrial, junc-
ional, or ventricular automaticity (with ectopic beats or
achycardia) often combined with AV block.
In mild cases, management includes discontinuing the
rug, monitoring rhythm, and maintaining normal serum
otassium. Occasionally, temporary pacing may be needed.
or more severe intoxication (serum digoxin concentration
reater than 4 to 5 ng/mL, and with serious arrhythmias),
he treatment of choice is digoxin-specific Fab antibody
290).
. Drug-Induced Long QT Syndrome
ecommendations
lass I
In patients with drug-induced LQTS, removal of the
offending agent is indicated. (Level of Evidence: A)
lass IIa
. Management with intravenous magnesium sulfate is
reasonable for patients who take QT-prolonging
drugs and present with few episodes of torsades de
pointes in which the QT remains long. (Level of
Evidence: B)
. Atrial or ventricular pacing or isoproterenol is rea-
sonable for patients taking QT-prolonging drugs
who present with recurrent torsades de pointes.
(Level of Evidence: B)
lass IIb
Potassium ion repletion to 4.5 to 5 mM/L may be
reasonable for patients who take QT-prolonging
drugs and present with few episodes of torsades de
pointes in which the QT remains long. (Level of
Evidence: C)
Marked QT prolongation, often accompanied by the
orphologically distinctive polymorphic VT “torsades de
ointes,” occurs in 1% to 10% of patients receiving QT
rolonging antiarrhythmic drugs, and much more rarely
n patients receiving “noncardiovascular” drugs with QT
rolonging potential. Table 9 lists those generally recog-
ized as having QT prolonging potential. An up-to-date
ist is maintained at www.torsades.org and www.qtdrugs
org.
QT intervals, uncorrected for rate, are generally greater
han 500 msec, prominent U waves are common, and
arked QTU prolongation may only be evident on
ost-pause beats. Major risk factors for drug-induced
orsades de pointes are listed in Table 10; often more
han one is present. Drugs can expose subclinical con-
enital LQTS; in addition, some studies have implicated
ore common DNA variants (polymorphisms, with fre-
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Drug Interacting Drug Effect
Increased Concentration of Arrhythmogenic Drug
igoxin Some antibiotics By eliminating gut flora that metabolize digoxin,
some antibiotics may increase digoxin
bioavailability. Note: some antibiotics also
interfere with P-glycoprotein (expressed in the
intestine and elsewhere), another effect that can
elevate digoxin concentration
igoxin Amiodarone Increased digoxin bioavailability, reduced biliary and
renal excretion due to P-glycoprotein inhibition
Quinidine
Verapamil
Cyclosporine Digoxin toxicity
Itraconazole
Erythromycin
uinidine Ketoconazole Increased drug levels
isapride Itraconazole
erfenadine, astemizole Erythromycin*
Clarithromycin
Some calcium blockers*
Some HIV protease inhibitors
(especially ritanovir)
eta blockers, propafenone Quinidine (even ultra-low dose) Increased beta blockade
Fluoxetine Increased beta blockade
lecainide Some tricyclic antidepressants Increased adverse effects
Decreased analgesia (due to failure of
biotransformation to the active metabolite
morphine)
ofetilide Verapamil Increased plasma dofetilide concentration due to
inhibition of renal excretion
Cimetidine
Trimethoprim
Ketoconazole
Megestrol
Decreased Concentration of Antiarrhythmic Drug
igoxin Antacids Decreased digoxin effect due to decreased
absorption
Rifampin Increased P-glycoprotein activity
uinidine, mexiletine Rifampin, barbiturates Induced drug metabolism
Synergistic Pharmacological Activity Causing Arrhythmias
T-prolonging antiarrhythmics Diuretics Increased torsades de pointes risk due to diuretic-
induced hypokalemia
eta blockers Amiodarone, clonidine, digoxin,
diltiazem, verapamil
Bradycardia when used in combination
igoxin Amiodarone, beta blockers,
clonidine, diltiazem,
verapamil
erapamil Amiodarone, beta blockers,
clonidine, digoxin, diltiazem
iltiazem Amiodarone, beta blockers,
clonidine, digoxin, verapamil
lonidine Amiodarone, beta blockers,
digoxin, diltiazem, verapamil
miodarone Beta blockers, clonidine,
digoxin, diltiazem, verapamil
ildenafil Nitrates Increased and persistent vasodilation; risk of
myocardial ischemiaThese may also accumulate to toxic levels with co-administration of inhibitor drugs like ketoconazole. Data are from Roden DM, Anderson ME. Proarrhythmia. In: Kass RS,
lancey CE, editors. Handbook of Experimental Pharmacology: vol. 171. Basis and Treatment of Cardiac Arrhythmias. Boston: Springer Verlag, 2006:288–304 (289).
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291,292).
Intravenous magnesium can suppress episodes of torsades
e pointes without necessarily shortening QT, even when
erum magnesium is normal (293). Temporary pacing is
ighly effective in managing torsades de pointes that is
ecurrent after potassium repletion and magnesium supple-
entation.
. Sodium Channel BlockerRelated Toxicity
ecommendations
lass I
In patients with sodium channel blockerrelated
toxicity, removal of the offending agent is indicated.
(Level of Evidence: A)
lass IIa
. Stopping the drug, reprogramming the pacemaker or
repositioning leads can be useful in patients taking
sodium channel blockers who present with elevated
defibrillation thresholds or pacing requirement.
(Level of Evidence: C)
. In patients taking sodium channel blockers who
present with atrial flutter with 1:1 AV conduction,
withdrawal of the offending agent is reasonable. If
the drug needs to be continued, additional A-V
nodal blockade with diltiazem, verapamil or beta
blocker or atrial flutter ablation can be effective.
(Level of Evidence: C)
lass IIb
Administration of a beta blocker and a sodium bolus
able 9. Examples of Drugs Causing Torsades de Pointes*
Frequent (greater than 1%) (e.g., hospitalization for monitoring
recommended during drug initiation in some circumstances)
● Disopyramide
● Dofetilide
● Ibutilide
● Procainamide
● Quinidine
● Sotalol
● Ajmaline
Less frequent
● Amiodarone
● Arsenic trioxide
● Bepridil
● Cisapride
● Anti-infectives: clarithromycin, erythromycin, halofantrine,
pentamidine, sparfloxacin
● Antiemetics: domperidone, droperidol
● Antipsychotics: chlorpromazine, haloperidol, mesoridazine,
thioridazine, pimozide
● Opioid dependence agents: methadone
See www.torsades.org for up-to-date listing. Adapted with permission from Roden
M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013–
2. Copyright © 2004 Massachusetts Medical Society (294).may be considered for patients taking sodium chan- Snel blockers if the tachycardia becomes more frequent
or more difficult to cardiovert. (Level of Evidence: C)
Arrhythmias caused by sodium channel blocking drugs
re included in Table 11. Antiarrhythmic drugs are the most
ommon precipitants, although other agents, notably tricy-
lic antidepressants and cocaine, may produce some of their
oxicities through these mechanisms. In large clinical trials,
odium channel blocking drugs have increased mortality
mong patients convalescing from myocardial infarction.
Animal and clinical anecdotes suggest that administration
f sodium, as sodium chloride or sodium bicarbonate, may
e effective in the reversing conduction slowing or frequent
r cardioversion-resistant VT (295,296). Beta blockers have
lso been used successfully (297).
. Tricyclic Antidepressant Overdose
ricyclic antidepressants are second only to analgesics as a
ause of serious overdose toxicity. Typical cardiac manifes-
ations include sinus tachycardia, and PR and QRS prolon-
ation and occasionally a Brugada syndrome-like ECG
298).
QRS duration can be shortened in experimental animals
nd in humans by administration of NaHCO3 or NaCl
oluses (299). Antipsychotic agents well known to produce
arked QT prolongation and torsades de pointes include
hioridazine and haloperidol.
. Other Drug-Induced Toxicity
ecommendations
lass I
. High intermittent doses and cumulative doses ex-
ceeding the recommended levels should be avoided
in patients receiving anthracyclines such as doxoru-
bicin. (Level of Evidence: B)
able 10. Risk Factors for Drug-Induced Torsades de Pointes
● Female gender
● Hypokalemia
● Bradycardia
● Recent conversion from atrial fibrillation
● Congestive heart failure
● Digitalis therapy
● High drug concentrations (exception: quinidine), often due to drug
interactions
● Rapid rate of intravenous drug administration
● Baseline QT prolongation
● Ventricular arrhythmia
● Left ventricular hypertrophy
● Congenital long QT syndrome
● Certain DNA polymorphisms
● Severe hypomagnesemia
● Concomitant use of 2 or more drugs that prolong the QT interval
● Combination of QT-prolonging drug with its metabolic inhibitor
dapted with permission from Roden DM. Drug-induced prolongation of the QT
nterval. N Engl J Med 2004;350:1013–22. Copyright © 2004 Massachusetts Medical
ociety (294).
DNA  deoxyribonucleic acid.
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receive close supervision and immediate discontinu-
ation of the infusion if symptoms or signs of myo-
cardial ischemia occur. Further treatment with
5-fluorouracil must be avoided in these individuals.
(Level of Evidence: C)
. Patients with known cardiac disease should have a full
cardiac assessment including echocardiography, which
should be undertaken prior to use of anthracyclines
such as doxorubicin, and regular long-term follow up
should be considered. (Level of Evidence: C)
Anthracycline cardiotoxicity is dose dependent with in-
ermittent high doses and higher cumulative doses increas-
ng the risk of cardiomyopathy and lethal arrhythmias
300,301). Risk factors include younger age, female gender,
nd use of trastuzimab (300,302–304). This form of cardio-
yopathy can occur acutely soon after treatment, within a
ew months of treatment (the so called subacute) form, or
any years later (301,305–311).
5-Fluorouracil causes lethal and potentially fatal arrhyth-
ias irrespective of underlying coronary disease during the
cute infusion period, the vast majority during the first
dministration (312). Cardiac monitoring during the infu-
ion period, especially the first, is recommended for all
able 11. Syndromes of Drug-Induced Arrhythmia and Their M
Drugs Clinical Settin
igitalis Mild cardiac toxicity (isolated arrhyth
Severe toxicity: sustained ventricular a
AV block; asystole
T-prolonging drugs Torsades de pointes: few episodes, QT
Recurrent torsades de pointes
odium channel blockers Elevated defibrillation or pacing requi
Atrial flutter with 1:1 AV conduction
Ventricular tachycardia (more frequen
Brugada syndrome
Always includes recognition, continuous monitoring of cardiac rhythm, withdrawal o
han 4 mEq/L), and oxygenation. The order shown is not meant to represent the p
AV  atrioventricular; IV  intravenous.atients receiving 5-fluorouracil therapy. rCocaine has both slow offset sodium channelblocking
roperties as well as QT-prolonging (IKr-blocking) proper-
ies. Arrhythmias associated with cocaine ingestion include
ide-complex tachycardias suggestive of sodium channel
lock (and responding to sodium infusion) as well as
orsades de pointes. Cocaine also causes other cardiovascular
omplications that can lead to arrhythmias, notably myo-
arditis and coronary spasm.
X. CONCLUSIONS
CD continues to be a major cause of mortality in all
eveloped countries. Using an evidence-based approach,
his document attempts to summarize the latest information
ddressing the problem, trying as much as possible to
rovide recommendations consistent with previous docu-
ents. However, it is important to stress that the field is
volving and recommendations will certainly change as we
earn more about the problem. The lengthy list of references
erves as an indication of the large amount of research
ddressing SCD already, and undoubtedly, the list will
ontinue to grow in the future. Timely updates of this
nformation will be critical as we try to care for patients at
ement
Management*
nly)
mias; advanced Anti-digitalis antibody
Pacing
Dialysis for hyperkalemia
ains long IV magnesium sulfate (MgSO4)
Replete potassium (K) to 4.5 to 5 mEq/L
Ventricular pacing
Isoproterenol
t Stop drug; reposition leads
Diltiazem, verapamil, beta blocker (IV)
cult to cardiovert) Beta blocker; sodium
Stop drug; treat arrhythmia
ding agents, restoration of normal electrolytes (including serum potassium to greater
d sequence when more than one treatment is listed.anag
g
mias o
rrhyth
rem
remen
t; diffi
f offenisk of SCD.
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